Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Buzz

Evaluate and EP Vantage Mentioned in the Press or Industry Reports

 December 2017

Shire expands orphan drug portfolio - European Biotechnology, December 1, 2017
"According to figures of EvaluatePharma, Shire is currently the market leader in the orphan non-oncology field. The analysts predict Shire’s orphan drug revenues to grow from US$5.4bn in 2016 to US$9.8bn by 2022"

Better Buy: Pfizer Inc. vs. Johnson & Johnson - Madison.com, December 1, 2017
"Earlier this year, research firm EvaluatePharma ranked J&J's pipeline as the fifth-best among big pharma companies, while Pfizer didn't make the top five list."

 November 2017

“Gold rush towards oncology” has major implications for pharma patent deal-making - IAM, November 30, 2017
"IAM recently spoke exclusively to Antonio Iervolino, head of forecasting at EvaluatePharma – a life sciences industry intelligence provider – about key trends in the pharmaceuticals space, and how they might impact on patent strategy." 

Pharm Exec's 2018 Pipeline Report - Pharm Exec, November 30, 2017
"* Source for all tables: EvaluatePharma®, September 2017, Evaluate Ltd"

The 10 most popular stories in Endpoints News — so far in 2017 - Endpoints News, November 24, 2017
"It tells us who's doing the best work, which companies have the best prospects and where the big bets are being made. There's a lot more to this than peak sales, but the drugs picked by EvaluatePharma represent a veritable treasure trove of blockbusters worth potentially more than $30 billion. Check it ..."

Loxo Oncology inks 'mega-bucks' deal with German pharma major - The Pharma Letter, November 14, 2017
"... see it steal a march on its archrival, Ignyta, commented EP Vantage, the editorial arm of the Evaluate group, at the time the results were announced."

Underestimate biosimilars at your peril, experts warn - The Pharma Letter, November 10, 2017
Lisa Urquhart, editor of the analysis provider EP Vantage, considered the potential consequences of the controversially low take-up of biosimilar ..."

Look back at Pharma news to Nov 3 - The Pharma Letter, November 5, 2017
"... Accelerator Applications' radiopharmaceutical Lutathera is odds-on for US approval, on the second time of asking, in January, opined EP Vantage, "

 October 2017

How Aubagio became the most switched-to oral MS drugMM&M, October 31, 2017
“Fast forward to 2017, during which Aubagio is expected to enjoy a robust 21% jump in sales vis-à-vis 2016 — from $1 billion to $1.2 billion, EvaluatePharma reports…”

Ozanimod MS data brings some relief for stumbling CelgeneChemdiv, October 30, 2017
“According to Evaluate Pharma, sales of ozanimod could reach more than $2 million by 2020 in MS alone, and if it also comes through in the Crohn’s disease and ulcerative colitis indications, the combined peak sales figure might be $5 billion. Celgene added the drug to its pipeline in 2015 by acquiring Receptos for $7.2 billion…”

New vaccine voted 'preferred' prevention for shingles virusFaribault.com, October 27, 2017
“The life-science analysis and forecasting firm EvaluatePharma predicts that Shingrix will have blockbuster sales of $1.126 billion by 2022. Sales of Merck’s Zostavax were $685 million last year…”

Natural selection: What should life science start-ups bear in mind when seeking funding? - EPM, October 27, 2017
“6. EP Vantage data..”

Breakthrough status for BioMarin ratchets up haemophilia A competitionPharmaphorum, October 27, 2017
“EP Vantage predicts emicizumab sales could reach $1.5 billion by 2022, taking a sizeable portion of a global market worth around $11 billion that is currently dominated by Novo Nordisk and Shire…”

MediciNova’s repurposed stroke and asthma drug clears MS trial FierceBiotech, October 26, 2017
“Ocrevus’ first-to-market position in both relapsing-remitting and primary progressive MS has put it on course for sales north of $4 billion by 2022, according to EvaluatePharma, but MediciNova is hoping that there will be an opportunity to grab a slice of the market for its orally active small-molecule drug. ..”

Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter Motley Fool, October 26, 2017
“Bictegravir is the most important asset that helped Gilead’s pipeline rank No. 4 in the biopharmaceutical industry in EvaluatePharma’s analysis earlier this year…”

The Repurposed Stroke and Asthma Drug that MediciNova Created Clears MS TrialBiotechStocks, October 26, 2017
“Ocrevus had a first-to-market position in both relapsing-remitting and primary progressive MS, which put it on a course for sales of more than $4 billion by 2020, according to EvaluatePharma...”

GSK’s new vaccine voted ‘preferred’ prevention for shingles virusThe Inquirer, October 25, 2017
“The life science analysis and forecasting asset that helped Gilead’s pipeline rank No. 4 in the biopharmaceutical industry in EvaluatePharma’s analysis earlier this year…”

Alzheimer’s immunotherapy boosted by AbbVie dealFinancial Times, October 24, 2017
“Analysts have predicted blockbuster revenues for these cancer drugs — with EvaluatePharma forecasting more than $200bn of sales for the top four checkpoints between 2017 and 2022 — prompting the pharma industry to investigate whether a similar approach could work in other disease areas such as neurodegeneration…”

Securing the cold chain with new solutions Pharmafile, October 23, 2017
“This builds on a trend already occurring that has seen the number of heat-sensitive products increase by 45% from 2011 to 2017, with such medicines now accounting for one in every two products, according to a report by Evaluate Pharma…”

An alternate look at pharmaceutical world revenues and drug affordabilityManufacturing Chemist, October 23, 2017
“World Preview 2017, Outlook to 2022, published by EvaluatePharma, is an interesting report.1...”

Should You Avoid Celgene Stock After Its Big Pipeline Setback?Madison.com, October 22, 2017
“Market research firm EvaluatePharma calculated a net present value for GED-0301 of $3.3 billion before the late-stage failure…”

New GlaxoSmithKline shingles vaccine gets FDA approval - Pharmacy Choice, October 21, 2017
“Based on the efficacy and safety profile, and incidence of shingles one in three people develops the virus life science analysis firm EvaluatePharma predicts Shingrix will have blockbuster sales of $1.126 billion by 2022…”

FDA approves a new vaccine for shingles that provides broad protectionSTAT News, October 20, 2017
“EvaluatePharma estimates the worldwide sales potential for the vaccine to top $1 billion a year within five years...”

Celgene Weighs Fate of Crohn's Candidate GED-0301 after Phase III FailuresGenetic Engineering & Biotechnology News, October 20, 2017
“Ozanimod has been projected by EvaluatePharma to reach $2.1 billion in revenues by 2022…”

Ozanimod MS data brings some relief for stumbling CelgeneThe Pharma Letter, October 20, 2017
“According to EvaluatePharma, sales of ozanimod could reach more than $2 million by 2020 in MS alone, and if it also comes through in the Crohn’s disease and ulcerative colitis indications, the combined peak sales figure might be $5 billion…”

How CNN reported on NuedextaCNN, October 20, 2017
“Reporters also reviewed government reimbursement data from EvaluatePharma and January 2017 pricing data from First Databank Inc., which tracks a commonly used drug price indicator known as the wholesale acquisition cost (WAC)…”

What Happened in the Stock Market TodayBillings Gazette, October 20, 2017
“Industry analysis service EvaluatePharma estimated in May that the net present value of mongersen sales is $3.3 billion, so this is certainly a blow to Celgene, with revenue currently running at about $12 billion a year and expected to grow to $21 billion by 2020…”

Review of Pharma news to Oct 20The Pharma Letter, October 20, 2017
“Bullish Celgene analysts would have investors believe that the failure of its late-stage Crohn’s disease project mongersen just clears the way for an even more promising candidate, ozanimod, noted EP Vantage, the editorial arm of the Evaluate group…”

China biotech's 'coming out party' masks long road ahead Reuters, October 19, 2017
“But the CFDA head lamented in a recent speech that Chinese domestic drug industry R&D investment was only 42 billion yuan ($6.3 billion) last year, a small slice of the $157 billion spent worldwide by drug companies in 2016, according to market intelligence group EvaluatePharma…”

Gilead Gets FDA Approval for New Cancer Therapy - Wall Street Journal, October 18, 2017
“Yescarta, the crown jewel of Gilead’s recent purchase of biotech Kite Pharma, has been among the most highly anticipated new drugs on Wall Street, which estimates  the therapy will have $1.7 billion spent worldwide by drug companies in 2016, according to market intelligence group EvaluatePharma…”

Gilead shares rise after FDA approves cell-therapy drug YescartaMarketWatch, October 18, 2017
“Yescarta, the crown jewel of the Gilead’s recent purchase of biotech Kite Pharma, has been among the most highly anticipated new drugs on Wall Street, which estimates the therapy will have $1.7 billion in world-wide sales in five years, according to EvaluatePharma, a market-research firm…”

J&J ups forecast after keeping biosimilars at bayPharmaphorum, October 18, 2017
“It is predicted to eventually become the firm’s biggest seller, with peak sales forecast by EP Vantage to reach $9.4 billion…”

Mass. biotechs flush with cash as VC dollars pour in Boston Business Journal, October 18, 2017
Article behind paywall.

MassBio Industry Snapshot 2017 - MassBio, October 17, 2017
"with support from Evaluate Ltd"

Finding the Perfect Match in FundingThe Journal of mHealth, October 13, 2017
“1. EP Vantage data…”

Why 2017 Could Be This Stock's Best Year YetFool.com, October 13, 2017
“Market research firm EvaluatePharma believes that Imbruvica will rank as the No. 4 cancer drug in terms of sales by 2022, with annual revenue of $7.5 billion…”

AZ starts pursuit of lung cancer indication for ImfinziPMLive, October 10, 2017
“Claiming first-line approval would accelerate sales of the drug, which have been tipped to reach $2.5bn or more in 2022, according to EvaluatePharma…”

Gilead completes $11.9bn Kite acquisitionPharmaphorum, October 4, 2017
“Evaluate Pharma predicts that sales of Kite’s drug could peak at around $7.9 billion, compared with $4.7 billion for Novartis’ CAR-T…”

E&C takes up right-to-tryPolitico, October 2, 2017
“The reason, says this EP Vantage story, was the surprising November election results…”

 September 2017

Medtech sales to reach $522bn by 2022 - European Pharmaceutical Review, September 26, 2017
"In-vitro diagnostics is expected to remain the largest medtech segment in 2022, with annual sales of $70bn, according to a report by Evaluate. Roche ..."

Look back at pharma news to Sept 22 - The Pharma Letter, September 23, 2017
"... valuation should allow Ultragenyx to win an acquisition battle for Dimension Therapeutics, says EP Vantage, the editorial arm of the Evaluate group."

Pfizer, Celgene and Roche are climbing pharma VC league table - FierceBiotech, September 1, 2017
"According to a new report from EP Vantage, Pfizer, Celgene and Roche are among drugmakers whose strategic venture arms are becoming ..."

 August 2017

Can Better Diagnostics Cure Our Healthcare System?Med Device Online, August 29, 2017
“According to an EvaluateMedTech reportfrom last year, annual world-wide sales of in vitro diagnostics (IVDs) are projected to swell to over $70 billion by the year 2022…”

Gilead Buys Kite Pharma, Founded by Israelis, for $11.9 BillionHaaretz, August 29, 2017
“Analysts predict axi-cel would have worldwide sales of $1.7 billion in 2022, according to EvaluatePharma…”

Gilead Sciences va racheter Kite Pharma pour 11,9 mrd USDRomandie, August 28, 2017
“En mai, le cabinet d'études EvaluatePharma valorisait Axi-cel à 7,4 milliards de dollars, ce qui en faisait l'un des 10 plus importants actifs pharmaceutiques en développement au monde…”

Special Report - The top companies in medtech by 2016 revenue FierceBiotech, August 28, 2017
“This report is based on data from life science intelligence firm, Evaluate…”

Transactiesom bedraagt circa 11 miljard dollar.DAH, August 28, 2017
“Kite's belangrijkste behandeling, axi-cel, moet nog goedgekeurd worden door Amerikaanse en Europese toezichthouders. Analisten voorzien dat in 2022 een jaarlijkse omzet van 1,7 miljard dollar wereldwijd mogelijk moet zijn met axi-cel, meldde EvaluatePharma. ..

Top 25 vaccine products in 2016, based on U.S. salesMM&M, August 28, 2017
“indicates sales figures for this product represent franchise-level sales that have been assigned by Evaluate to the lead product in the franchise [...] Source: EvaluatePharma, August 2017"

Look back at pharma news to Aug 25The Pharma Letter, August 28, 2017
Article behind paywall

Samsung chce být farmaceutickým obrem Ekonomiky denik, August 28, 2017
“Podle výzkumné instituce Evaluate Pharma by do roku 2022 měl trh s léky na předpis růst o 6,5 procenta ročně a dosáhnout obratu, přesahujícího jeden bilion dolarů (přes 22 bilionů korun)…”

Gilead Bets $11 Billion on New Cancer TherapyWall Street Journal, August 28, 2017

Gilead to Buy Kite Pharma for Roughly $11 Billion in CashDow Jones, August 28, 2017
“Analysts predict it would have world-wide sales of $1.7 billion in 2022, according to EvaluatePharma, which ranks the drug among the industry’s top 10 compounds in terms of sales potential…”

Special report – the top ten cardiovascular drugs in the world FiercePharma, August 28, 2017
Competition, particularly with low-cost generics, will be fierce, however; the cholesterol drug market is expected to be worth just $13.4 billion in 2022, a slight decline from last year, while hypertension remedies are also expected to shrink a bit, to $24.4 billion, according to Evaluate Pharma estimates made earlier this year.

Gilead comprará Kite Pharma por 11.900 millones de dólaresABC Economia, August 28, 2017
“Los analistas estiman que las ventas del fármaco en todo el mundo podrían alcanzar los 1.700 millones de dólares en 2022, según EvaluatePharma…”

Gilead at last spending some of its cash pile on an acquisitionThe Pharma Letter, August 28, 2017
Article behind paywall.

Case farmaceutiche: Gilead Sciences acquisirà Kite per 11,9 miliardiSky, August 28, 2017
“La scommessa su Kite dipende essenzialmente dal successo del farmaco axi-cel, il cui potenziale in termini di fatturato globale potrebbe raggiungere gli 1,7 miliardi di dollari entro il 2022, stima l'agenzia di settore EvaluatePharma. ..”

Why I Love AbbVie Inc. – Lincoln Journal Star, August 27, 2017
“Market research firm EvaluatePharma thinks the biotech has the No. 3 pipeline in the biopharmaceutical industry…”

Ardelyx (ARDX): Looking Ahead After Restructuring Equities, August 25, 2017
“Additionally, according to EvaluatePharma, tenapanor's CSBM responder rate was worse than the rate shown by two competing products from Allergan/Ironwood Pharmaceuticals (NYSE: AGN; Nasdaq: IRWD) and Synergy Pharmaceuticals (Nasdaq: SGYP)…”

Samsung Се Разширява Към Фармацевтичния ПазарCapital, August 23, 2017
“Evaluate Pharma смята, че продажбите на лекарства с рецепти ще нарастват с 6.5% в следващите години и пазарът ще достигне 1.06 трлн. долара през 2022 г…”

Samsung Broadens Its Drugs Business Business Standard, August 22, 2017
“The lucrative biologics market is expected to generate $214 billion in sales this year, according to EvaluatePharma, a source of pharmaceutical market data and analysis…” *Also Appeared in  CETUS News

3 Most Promising Cancer Drugs in Late-Stage Development - Motley Fool, August 22, 2017
“Market research firm EvaluatePharma evaluated all of the experimental cancer drugs in late-stage development…”

An Analysis Of 2017 First Half For Pharmaceutical Industry Goinpharma, August 18, 2017
“The future of the pharmaceutical industry, however, does not look so rosy, indeed, according to Evaluate Pharma, revenues will decline for the first time over the next years (2022)…”

Disse selskaber hyrer og fyrer mestMedwatch, August 18, 2017
Article is behind paywall.

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’sLabiotech, August 18, 2017
“These results further strengthen the potential of semaglutide, which has already been named one of the most valuable pharma R&D projects of the year by Evaluate Pharma, which expects the drug to reach sales of $2.24Bn (€1.9Bn) in 2022…”

FDA approves Pfizer’s Besponsa in aggressive blood cancer Pharmaphorum, August 18, 2017
“According to consensus figures from EvaluatePharma, sales forecasts are modest at $347m by 2022, and UCB also has worldwide royalties…”

The decade's top 10 patent losses, worth a whopping $915B in lifetime sales FierceBiotech, August 17, 2017
Together, the 10 biggest drugs losing IP protections since 2007 will account for more than $915 billion in lifetime sales, according to data compiled by life science commercial intelligence firm Evaluate…”

The Growth of Orphan Drugs Therigy, August 15, 2017
“EvaluatePharma predicts an annual sales growth forecast of 11 percent – more than double the predicted rate for conventional drugs…”

Changing Administrations and the Strategy for Value-Based Growth in MedtechOrthopedic Design & Technology, August 15, 2017
“According to EvaluateMedtech,2 the global market for medical devices will achieve $529.8 billion in sales in 2022, expanding at a 5.2 percent compound annual growth rate (CAGR) between 2015 and 2022…”

Мировой Фармацевтический Рынок В 2016 Году: «В Бурных Водах» - Pharm.Reviews, August 15, 2017
“Источник: Evaluate Pharma, 2016, World Preview 2016 outlook to 2022. Данные рассчитаны на основе цен производителя без учета скидок за счет законодательного снижения отпускных цен…”

Why Has 2017 Been A Horrible Year So Far For Biotech Acquisitions?Citybizlist, August 14, 2017
“DATA SOURCE: EVALUATEPHARMA. CHART BY AUTHOR…”

How to Make Money off America’s Opioid Epidemic Nanalyze, August 14, 2017
“Based on 2015 sales, the top five opioid products were made by Purdue Pharma, Johnson & Johnson, Insys Therapeutics, Mylan and Depomed, according to EvaluatePharma, a life sciences market intelligence firm, which tracks sales…”

4 Korean Pharmaceuticals Make Waves in Immunotherapy Market Korean Biomedical Review, August 12, 2017
“According to leading consulting group Evaluate Pharma, global prescription drug sales will hit $1.06 trillion by 2022, with most of the growth coming from new immunotherapies such as Opdivo and Keytruda…”

Top 25 Oncology Brands In 2016, Based On U.S. Sales MM&M, August 11, 2017
“Source: EvaluatePharma, June 2017, Evaluate "

Erste Asset Management Sieht Rückenwind Für Biotech-Aktien Fonds Exklusiv, August 11, 2017
“„2016 stammten bereits 60% aller Medikamenten-Zulassungen aus den Labors von Biotechnologie-Unternehmen“, wie Kober unter Berufung auf Zahlen von Evaluate Pharma feststellt…”

In an era of mega-rounds, Roivant Sciences still makes a splash with $1.1B haul MedCity News, August 10, 2017
“Two new reports by Evaluate Ltd’s news and analysis arm, EP Vantage, highlight the wider trend…”

Novartis claims EU approval for breast cancer drug KisqaliPMLive, August 8, 2017
“Novartis can now compete with Ibrance (palbociclib) on two fronts as it tries to chase down Pfizer's drug, which brought in $2.1bn in sales last year and - according to EvaluatePharma - will grow into a $6bn product in 2022, well ahead of Kisqali which it says will be a $1.6bn brand by that year…”

Branża Farmaceutyczna Zwalnia PracownikówPolityka Zdrowotna, August 7, 2017
“EP Vantage postanowiła sprawdzić raporty finansowe największych producentów farmaceutycznych na świecie z końca 2016 r. Wynika z nich, że jedynie trzy koncerny ze światowej czołówki stworzyły dodatkowe miejsca pracy…”

Relevance of Outliers In Pharma Sales ForecastingPilman, August 7, 2017
“The sample for this study comprised 210 new drugs launched between 2003 and 2009, for which McKinsey gathered necessary consensus-forecasts data for launch from EvaluatePharma…”

AbbVie (ABBV) Wins FDA Approval for the First-Ever Drug to Treat All Forms of Hep CBioSpace, 4 August, 2017
“Sales of Mavyret are pegged at about $1.3 billion by 2022, EvaluatePharma said, as reported by Endpoints News. However, Gilead dominates the HCV market and does so for a reason…”

Sector analysis: Pharmaceuticals - are drug companies on a high? - Capital.com, August 3, 2017
“In its annual review, industry analysts EvaluatePharma forecast that by 2022, worldwide drug sales would hit $1.06 trillion…”

Japanese Pharmaceutical Market Set To GrowManufacturing Chemist, August 3, 2017
“According to Evaluate, a life science commercial intelligence firm, the Japanese pharmaceutical market is set to grow at a compounded average growth rate (CAGR) of 3.3% between 2017 and 2022, significantly lower than the worldwide outlook (6.5% CAGR)…”

Pulling away from the pack in drug launches  – Nature Reviews Drug Discovery, August 3, 2017
“We examined US launches from 2006 to 2013 to evaluate 3- and 5-year data (not available for launches in 2012 and 2013) after launch, using revenue data from the EvaluatePharma database and multivariate regression analysis. Here, we present the key findings from our analysis (see Supplementary information S1 (box) for details of the data set and analysis)….”

Biopharma Stages A Strong RecoveryEuropean Pharmaceutical Review, August 3, 2017
“After the first half of 2017, EvaluatePharma reports the healthy recovery of the US biopharmaceuticals industry…”

Sanofi, Glaxosmithkline and Astrazeneca Led Big Pharma's Layoffs In 2016: ReportFierceBiotech, August 3, 2017
“The numbers come courtesy of EP Vantage, which dug into the companies' year-end financial reports. Sanofi led the job-culling pack with an 8% workforce reduction, ending 2016 at 106,859, down from 115,631 when the year dawned…”

Nanotechnology to Beat Generic and Patent Cliff Ophthalmic Project Global Journal of Pharmacology, August 3, 2017
“Over the same time, Evaluate Pharma estimated that $1.1 trillion has been invested in R&D in a bid to revitalize pipelines…”

Samsung Îşi Face Intrarea Pe Piaţa Medicamentelor. „Elixirul” Pe Care Compania Vrea Să-L Vândă Cu 760 De DolariAgora, August 2, 2017
“Piaţa medicamentelor a înregistrat produse vândute anul trecut în valoare de 202 miliarde de dolari, la nivel global, iar estimările făcute de EvaluatePharma anunţă încasări de 214 miliarde pentru anul acesta…”

Clock Starts Ticking On FDA Review of AZ's AcalabrutinibPMLive, August 2, 2017
“If approved, acalabrutinib would have the task of taking on Imbruvica, which had sales of more than $2.2bn last year in its approved indications - chronic lymphocytic leukaemia (CLL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL) and MCL - and according to EvaluatePharma (EP) is due to reach $7.5bn in global sales by 2022, elevating it into the top 10 pharma products in that year…”

FDA Grants Fast Review to AZ Cancer Drug - Pharmaphorum, August 2, 2017
“According to Evaluate Pharma, AZ must find as many uses for the drug as possible if it is to recoup the $2.5 billion it paid for a controlling stake in US biotech Acerta Pharma in late 2015…”

The Value of Empowered CRAs in Rare Disease Studies Applied Clinical Trials, August 2, 2017
“(8) Hadjivasiliou A. EvaluatePharma Orphan Drug Report 2017. Evaluate group, February 2017."

2017 Annual Report – Top 200 Medicines: Humira Remains Atop the Throne - PharmaLive, August 1, 2017
“According to EvaluatePharma’s “World Preview 2017, Outlook to 2022” report, Humira is still expected to be the top-selling medicine in 2022 at $15.9 billion with a 28.7 percent global market share…”

Samsung Intră Și În Industria Farmaceutică?! Compania A Lansat Un Medicament, Care Costă Circa 750 $ - Joblist, August 1, 2017
“Piaţa medicamentelor a înregistrat produse vândute anul trecut în valoare de 202 miliarde de dolari, la nivel global, iar estimările făcute de EvaluatePharma anunţă încasări de 214 miliarde pentru anul acesta…”

Improved Phase 3/4 Research Designs Offset High Pricing: Sustained Via Recent M&As Life Science Leader, August 1, 2017
“This is not a “one-off”; the average pharmaceutical cost per orphan U.S. drug patient in 2016 was $140,443, and has risen from $116,216 in 2012, according to an analysis by EvaluatePharma…”

The Impact of Biosimilars on Global Pharmaceutical Markets Rothwell Figg, August 2017
“Evaluate Pharma’s 2017 World Preview reports that the entry of biosimilars into the global markets is expected to erode the total sales of biologic drugs by as much as 54% through 2022…”

 July 2017

Snippet Roundup: Oxford Jumps On Novartis' CAR-T And EU Regulators Think For Themselves - Seeking Alpha, July 7, 2017
"Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items. This week, July 3 to 7, 2017, we had thoughts on the ..."
 
Look back at pharma news to July 7- The Pharma Letter, July 9, 2017
"... a group that has had a consistent if low-key presence at recent oncology conferences, looks finally to have come of age, according to EP Vantage, ..."
 
The CTL019 Adcom Mists Begin To Clear
- Seeking Alpha, July 11, 2017
"Briefing documents to guide the review of Novartis' (NYSE:NVS) US filing for CTL019 seem to have made at least one thing clear: the focus of the ..."

Big Pharma share prices jumped in the first half, except for BMS - FiercePharma, July 11, 2017
"Bristol-Myers Squibb was the only company in EP Vantage's “big cap” category to post a share price decline over the first six months of the year, the ..."
 
Read the archive of STAT's live blog as we analyzed a crucial FDA meeting on experimental CAR-T cancer treatment - STAT, July 9, 2017
"Join STAT's Adam Feuerstein and Damian Garde plus EP Vantage's Jacob Plieth for an all-day live blog of the make-or-break meeting, starting at 8 ..."

FDA panel backs Novartis' pioneering new cancer gene therapy - HiTechFacts, July 13, 2017
"Other CAR-T groups could have an edge here: EP Vantage has previously calculated that the "vein-to-vein" time for Novartis' product is 29 days..."
 
Novartis' CAR Speeds Towards Approval With Panel Nod - Seeking Alpha, July 13, 2017
"... means that Kite might avoid a similar grilling, Stat reporter Damian Garde noted during a live blog yesterday in collaboration with EP Vantage."
 
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition - Madison.com, July 16, 2017
"EvaluatePharma projects 2022 sales of $227 million for filgotinib. However, the research firm didn't include any future sales estimates for selonsertib, ..."

Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter - Madison.com, July 16, 2017
"According to research firm EvaluatePharma, Novartis should push Pfizer out of the top position by 2022. Should Pfizer shareholders be concerned?"
 
Look back at Pharma news to July 14 - The Pharma Letter, July 16, 2017
"Commenting on last week's announcement of a $650 million-plus proposed takover of Protein Sciences by French pharma major Sanofi, EP Vantage, ..."

Delving For The Drivers Of Pharma's Disappearing Deals - Seeking Alpha, July 18, 2017
"The 24 M&A deals tallied by EvaluatePharma in the second quarter fell substantially below the five-year quarterly average of 57. Of course the 61 ..."

5 Big Pharma Stocks With the Best Drug Pipelines - Madison.com, July 18, 2017
"Market research firm EvaluatePharma recently released its report looking at the state of the biopharmaceutical industry five years from now. One key ..."

Delving For The Drivers Of Pharma's Disappearing Deals - Seeking Alpha, July 18, 2017
"Earlier this month EP Vantage's look at longer-term M&A data revealed a big drop in the number of transactions in the second quarter, prompting this ..."
 
FDA's Flashing Green Light Boosts Novel Drug Approvals - Seeking Alpha, July 19, 2017
"Unlike some other analyses of the FDA's data, EP Vantage includes drug approvals by the regulator's biologicals division CBER, as well as the more ..."

Novartis CEO says shopping for bolt-ons is tough. Why? Creeping biotech deal prices - FiercePharma, July 19, 2017
"Recent research from EP Vantage noted that the sector's deals totaled at $49.3 billion in value for the first half of 2017, lower than the same period for ..."
 
3 Big Pharma Companies With the Best Projected Return on Investment - Madison.com, July 19, 2017
"Research firm EvaluatePharma recently published its report of where the pharmaceutical industry could be in 2022. One of the firm's projections was ..."

Takeover Deals Weaken At Opposite Ends Of The Market - Seeking Alpha, July 20, 2017
"An analysis earlier this week looked at EvaluatePharma's M&A data in total - which included other transaction types like stake sales - while this ..."
 
Looking For Value In The Deal Sweet Spot - Seeking Alpha, July 20, 2017
"An analysis by EP Vantage reveals various targets at this price, but his comments suggest that investors have priced many out of the market (see table ..."

These 5 Drugs Could Be Worth $45 Billion - and They're Not Even on the Market Yet - Madison.com, July 23, 2017
"That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the ..."

 June 2017

Sanofi to Invest Further in Biologics - Reuters, June 2017
“Figures compiled by EvaluatePharma show conventional drugs still represented 70 percent of the top 100 medications sold worldwide before 2010, but that the proportion would narrow to 50 percent as soon as around 2022…”

Merck moves up sales rankings in vaccine industry projection - FiercePharma, June 30, 2017
"According to Evaluate analysts, the change comes as a result of market forecasters bumping up sales projections for Merck’s Gardasil and Pneumovax by $215 million and $268 million,"

Pharma Exec’s Top 50 Companies 2017 - Pharmaceutical Executive, June 28, 2017
"Pharm Exec’s 17th annual listing again features data provided by biopharma market intelligence firm Evaluate Ltd. "

Worldwide drug sales to hit $ 1.06 trillion in 2022: Study - Business Standard, June 27, 2017
“Increased scrutiny around the pricing of medicines is starting to have an impact on drug sales growth, according to Evaluate’s latest World Preview report…”

Bristol to receive £1 million gift to launch the next generation of researchers - University of Bristol, June 27, 2017
“He went on to found the Evaluate Group in 1996, the market intelligence leader in the life sciences industry, of which he is currently chairman…”

A Halftime Analysis of 2017 Drug Approvals - MedCity News, June 27, 2017
“Back in January, Evaluate Pharma forecast Dupixent could generate as much as $4.5 billion in sales annually by 2022, making it the biggest release of the year…”

Pharmakonzerne müssen sich auf sinkende Umsätze einstellen - DAZonline, June 26, 2017
“Erstmals seit zehn Jahren prognostiziert das auf die Pharmabranche spezialisierte Analyseunternehmen Evaluate Pharma zurückgehende Erlöse für die innovativen Arzneimittelhersteller…”

Data stacking up for Roche haemophilia A drug - Pharmaphorum, June 26, 2017
“Analysts Evaluate Pharma predict sales of $1.5 billion in 2022, making the drug one of the biggest sales hopes in Roche’s pipeline…”

After a slow 2016, FDA’s racking up drug approvals lickety-split - Borderless, June 26, 2017
“Analysts expect both to pass $4 billion in sales by 2022, representing this year’s biggest launches, according to EP Vantage….”

Could Valeant Pharmaceuticals Have Gifted Teva its "Biggest Commercial Hope"? - PharmExec, June 26, 2017
“It’s a move that could be the one that secures Teva’s existence, as EP Vantage explains: “The drug is one of Teva’s biggest commercial hopes outside its generics base, and the beleaguered company needs to show that it make can make the most of this opportunity…”

Vendas farmacêuticas podem cair pelo 390000 milhões até 2022 - Panorama Farmaceutico, June 26, 2017
“EvaluatePharma consultor cortou as previsões de vendas globais para a indústria farmacêutica para os sinais que apontam para um abrandamento da inflação dos preços dos medicamentos nos Estados Unidos…”

Farmacéuticas Podrían Recortar Sus Ingresos Durante 5 Años - Espiral21, June 25, 2017
“La consultora EvaluatePharma recorta las previsiones de ventas globales para la industria farmacéutica ante los indicios que apuntan a una relajación de la inflación en los precios de los medicamentos en EEUU…”

Las Ventas Del Sector Farmacéutico Podrían Caer En 390.000 Millones Hasta 2022 - Expansion, June 25, 2017
“La consultora EvaluatePharma ha recortado las previsiones de ventas globales para la industria farmacéutica ante los indicios que apuntan a una relajación de la inflación en los precios de los medicamentos en EEUU…”

The Multiple Sclerosis Market - Nature Reviews Drug Discovery, June 23, 2017

Эксперты Evaluate Pharma - тенденция на снижение прогнозов - Dosfarm, June 23, 2017
“Впервые за 10 лет эксперты Evaluate Pharma снижают прогноз по глобальному объему продаж лекарственных средств в 2022 г. на фоне ценового давления на американских рынках ключевых ЛП…”

Roche, Celgene Fight for No. 1 Spot in Oncology market - Korea Biomedical Review, June 23, 2017
“EvaluatePharma, which analyzes pharmaceuticals and biotech companies, said oncology, or cancer treatment, will be the fastest growing therapy area with an expected annual growth of 12.7 percent and sales reaching $192.2 billion in 2022…”

Orphan drug market set to climb above $200B: report - FiercePharma, June 22, 2017
" life science commercial intelligence firm Evaluate projects orphan drug sales will represent 32% of pharma’s total growth through 2022. "

Global Pharma Sales Face $60 Bn Hit Due To Pricing Scrutiny: Market Study - Business Standard, June 22, 2017
"Market intelligence firm Evaluate has cut the 2022 global pharmaceutical sales forecast by $60 billion amid rising scrutiny of drug pricing and price erosion in various markets."

Drug Stocks Like What The Trump Administration Is Saying About Regulating Drug Prices - Jubak Picks, June 22, 2017
“Industry watcher EvaluatePharma had cut its global revenue forecast for the drug industry by $390 billion for 2017-2022...”

Какие Фармацевтические Компании Претендуют На Глобальное Лидерство По Объему Продаж Через 5 Лет? - Pharma.Net.Ua, June 22, 2017
“Впервые за 10 лет эксперты Evaluate Pharma прогнозируют снижение глобального объема продаж лекарственных средств в 2022 году на фоне ценового давления на американском рынке, сообщает Фармвестник со ссылкой на Reuters…”

Warning Sounded On Pharma's Long-Term Sales Prospects - PMLive, June 21, 2017
“For the first time in a decade, EvaluatePharma has amended its long-term sales projections for the pharma industry downwards - thanks to pricing pressure, biosimilars and a dip in novel drug approvals…”

Evaluatepharma: Vendite Farmaci In Calo Dopo Dieci AnniDaily Health Industry, June 21, 2017
“È quanto emerge dal rapporto di EvaluatePharma…”

Global Drug Sales Forecast Falls For 1st Time In Decade - Becker’s Hospital Review, June 21, 2017
“Forecasts of worldwide drug sales decreased in 2017 amid growing price scrutiny on prescription medications, according to an Evaluate Pharma report…”

Odhady Globálních Tržeb Z Prodeje Léků Poprvé Za Deset Let Klesly - ZDravi, June 21, 2017
“Plyne to ze zprávy společnosti Evaluate Pharma, která sestavuje konsenzuální odhady založené na předpovědích analytiků…”

Report Suggests that Biosimilars May Slow Drug Sales Worldwide by 2022 - The Center for Biosimilars, June 21, 2017
“Worldwide prescription drug sales could reach $1.06 trillion by 2022, according to a new report produced by EvaluatePharma…”

Top 20 Blockbuster Drugs in The Late-Stage Pipeline - EvaluatePharma - Endpoints, June 21, 2017
“The new list from EvaluatePharma on the top 20 late-stage drugs in the pipeline — included in its big annual report on the industry — underscores just how hard that is, and also how much progress AbbVie is making...”

Global Pharma Sales Forecasts Cut Amid Pricing Pressures - Financial Times, June 21, 2017
“EvaluatePharma lowers projections for next 5 years by $400bn…”

Alerte Sur Les Valeurs Pharmaceutiques - Le Revenu, June 21, 2017
“EvaluatePharma a annoncé avoir réduit ses prévisions de chiffre d'affaires pour les grands groupes pharmaceutiques internationaux…”

Drug sales forecast to fall for first time in 10 years - The Pharma Letter, June 20, 2017

R&D costs growing, Roche shines and Novo high for ROI: It’s the EP report - FiercePharma, June 20, 2017
"EvaluatePharma has totted up the figures for R&D spend and costs for biopharmas, and the figures are huge: $4 billion per NME over the past decade..."

Worldwide Drug Sale Forecasts Fall As Pricing Pressures Mount - Reuters, June 20, 2017
“Evaluate Pharma, which compiles consensus numbers based on analysts' forecasts, said worldwide drug sales were now expected to hit $1.06 trillion in 2022, down from $1.12 trillion predicted a year ago for the same period…”

Odhady Globálních Tržeb Z Prodeje Léků Poprvé Za Deset Let Klesly - finance.cz, June 20, 2017
“\"Zvýšená politická a veřejná pozornost věnovaná cenám nových i starých léků neopadne a nyní začínáme pociťovat její vliv,\" uvedl ke zprávě Antonio Iervolino, který vede prognostické oddělení Evaluate Pharma…”

Pricing Pressure and Patent Expirations Force A Drop In Projected Drug Sales - STAT News, June 20, 2017
“Ongoing controversy over drug prices and a rising number of patent expirations on some big-selling medicines has prompted a downward revision in global sales over the next five years, according to EvaluatePharma, a market research firm…”

The Amount You Pay for Cancer Drugs May Double - Here's Why - Motley Fool, June 19, 2017
“According to a recently published article from MarketWatch, which referenced an EP Vantage/Evaluate Report, the number of ongoing and completed trials involving cancer immunotherapies has quadrupled to nearly 800 from about 200 in the fall of 2015. ..”

Sandoz Joins Europe's Mabthera Biosimilar Push - PMLive, June 19, 2017
“Biosimilars that are currently on the market are predicted by EvaluatePharma to lose around $4.5bn over the next five years. Most of that impact will be felt after biosimilars appear in the US, however, which Roche says it does not expect until after 2019. Sandoz has indicated it will file its biosimilar in the US later this year…”

Anofi Планирует Ежегодно Инвестировать В Разработку Биопродуктов 600 Млн Евро - Biocon.Bc, June 16, 2017
“Согласно данным EvaluatePharma, препараты химического синтеза в 2010 г. составляли 70% в топ-100 самых продаваемых в мире препаратов. По прогнозам аналитиков, примерно к 2022 г. их доля снизится до 50%...”

Pharm Exec's Top 50 Companies 2017 PharmExec, June 16, 2017
“As far as future shifts in sales-figure positioning in the Pharma 50, Jonathan Gardner, EP Vantage News Editor, US, at Evaluate, cites two areas to watch...”

AHCA May Help Kill U.S. Jobs - TYT Network, June 16, 2017
“In 2014, EP Vantage, which covers the med-tech industry, reported “stable” employment. Earlier this year, EP Vantage found “little impact from the medical device tax on employment in the sector…”

Sanofi Punta Forte Sui Biologici. 600 Mln Di Euro Nei Prossimi 2 Anni - Daily Health Industry, 15 June 2017
“Una stima che si allinea con quanto analizzato da un report di EvaluatePharma secondo il quale al 2010 i farmaci ‘convenzionali’ rappresentavano il 70% dei 100 prodotti più venduti al mondo: nel 2022 questa percentuale scenderà a meno del 50% a favore dei biologici…”

Sanofi Busca Aumentar Su Presencia En El Área De Los Biológicos - Mirada Profesional, 15 June 2017
“Las cifras recopiladas por EvaluatePharma muestran los fármacos convencionales aún representaban el 70 por ciento de los 100 mejores medicamentos vendidos en el mundo antes de 2010, pero que la proporción reduciría a 50 por ciento tan pronto como alrededor de 2.022, de acuerdo a la reseña de la agencia Reuters…”

Французская Компания Sanofi Планирует Ежегодно Инвестировать В Разработку Биопродуктов 600 Млн Евро - Pharma.Net.Ua, June 15, 2017
“Согласно данным EvaluatePharma, препараты химического синтеза в 2010 году составляли 70% в топ-100 самых продаваемых в мире препаратов. По прогнозам аналитиков, примерно к 2022 году их доля снизится до 50%...”

Quatre biotechs pour combattre le cancer (et gagner en Bourse) - Le Revenu, June 15, 2017
“Près de 765 essais cliniques sont en cours, selon les analystes d’EP Vantage. …”

Trump Health Care Tax Cut Could Lead to Layoffs, Not New Jobs - International Business Times, June 15, 2017
“In 2014, EP Vantage, which covers the med-tech industry, reported “stable” employment. Earlier this year, EP Vantage found “little impact from the medical device tax on employment in the sector…”

How a New SCOTUS Ruling Could Affect Pharma ETFs - ETF Trends, June 14, 2017
“Evaluate Pharma calculated that biologics with aggregate U.S. sales of $79 billion will lose their patent protection between 2013 and 2018…”

Sanofi Zvýší Investice Do Biologických Léčiv - Investicniweb, June 14, 2017
“Podle údajů analytické společnosti EvaluatePharma se konvenční léky do roku 2010 na stovce nejprodávanějších přípravků podílely 70 procenty, do roku 2022 se však tento podíl zřejmě sníží na 50 procent…”

Sanofi Commits $673 Million in Biologics - PharmaLive, June 14, 2017
“EvaluatePharma indicates that traditional drugs account for about 70 percent of the top 100 medications marketed globally prior to 2010, but that by 2022 that will slip to 50 percent, as biologics become a larger part of the market…”

How Merck hopes to win in I/O combos: Q&A with Roy Baynes - BioPharmaDive, June 14, 2017
“To that end, nearly 800 clinical trials are currently ongoing involving combinations of PD-1/L1 inhibitors, more than triple the numbers seen in 2015, according to data compiled by EP Vantage….”

The Commercial Outlook for Infectious Disease Vaccines - BioPharma Dealmakers, June 14, 2017

CAR-T Therapy: Personalized Medicine With The Promise Of A Cure; Payers Will Decide Who Gets It - Monday Morning, June 13, 2017
“Evaluatepharma Analysts Have Assessed The Kite Drug, KTE-C19 For Non-Hodgkin Lymphoma, As One Of The Top 10 Drug Launches Of 2017…”

Grail’s Billion Dollar Bet for the Perfect Cancer Test - Digital Pathology Blog, June 11, 2017
“Grail has raised $1.1 billion, a sum that puts it among the top three most heavily funded private biotech companies, according to Evaluate Pharma…”

A Quick Look At The Axitinib Data And IO/VEGF Inhibitor Combos - Sugarcone Biotech, June 11, 2017
“The magnitude of potential noise is illustrated in this graph from EvaluatePharma’s nice IO combo report…”

Bristol-Myers Squibb Loses $4.3 Billion in Market Value After ASCO Update - PharmaLive, June 7, 2017
“EP Vantage recently released a report in conjunction with ASCO that evaluated the status of PD-1/PD-L1 combination therapies…”

In Biotech, No News Is Bad News - Cetus News, June 7, 2017
“Just three drugs being introduced this year are expected to top $2 billion in annual sales by 2022, according to research firm Evaluate Pharma…”

Historic Moment For Chinese CAR-T Biotech - Cell Trials, June 6, 2017
“A buzz was rapidly escalated by big media outlets (Reuters, NBC, CBS and others) as well as by coverage of specialized biotech/ medical news journalists (see: EP Vantage, Endpoints, FierceBiotech and STAT)...”

BMS' Opdivo, Merck's Keytruda Lead Their Class in Cancer Vaccine Combo Studies: Report - FiercePharma, June 6, 2017
“Released in conjunction with the annual meeting of the American Society of Clinical Oncology, EP’s report documents 16 vaccine combo trials for Bristol’s Opdivo in a variety of indications, including lung cancer, brain cancer, ovarian cancer, melanoma and others…”

7 Things Doctors Are Buzzing About at The Biggest Cancer Research Meeting - Chicago Tribune, June 6, 2017
“A new report by EP Vantage, a news service that covers the pharmaceuticals and biotech industries, counts 765 combination studies involving the most prominent kind of immunotherapy listed on the federal database ClinicalTrials.gov…”

Checkpoint Combos for Cancer Are All the Rage as Trial Sponsors Line Up Hundreds of New Studies - Report - Endpoints, June 6, 2017
“Now EP Vantage has tallied the whole score on these combo trials, not coincidentally just ahead of ASCO, and found a stunning 765 combination studies listed on clinicaltrials.gov…”

ASCO Roundup: Checkpoint Combos, Tumor Profiling, Financial Toxicity - Xconomy, June 6, 2017
“Two days later, EP Vantage checked in with a tally of combo studies involving anti-PD-1 or anti-PD-L1 therapies…”

ASCO Round Up: Zytiga Shines In Frontline Prostate Role, Loxo And Incyte Pass Early Tests - Pharmaphorum, June 5, 2017
“According to analysts Evaluate Pharma, this could see Zytiga make up ground on Pfizer’s Xtandi…”

Roche Trumpets APHINITY Data, But Did It Hit The Mark? - PMLive, June 5, 2017
“A large chunk of Perjeta's $5bn sales forecast has been attributed to adjuvant use alongside Herceptin and chemo, according to EP Vantage…”

Is The Global Generic Drug Market Slowing Down? - Tippan, June 5, 2017
“This trend has been well captured in numbers, from various different angles, in the September 2016 report of Evaluate Pharma, as follows:”

Grail’s $1 Billion Bet on the Perfect Cancer Test - MIT Technology Review, June 5, 2017
”Grail has raised $1.1 billion, a sum that puts it among the top three most heavily funded private biotech companies, according to EvaluatePharma…”

Lilly Adds To Data Backing Breast Cancer Candidate Abemaciclib - PMLive, June 5, 2017
“Ahead of the conference Leerink analysts said it was too early to say how abemaciclib will stack up against Ibrance, which saw sales almost triple to reach $2.1bn last year and has been tipped by EvaluatePharma to become a $6bn-plus product in 2022, with Kisqali and abemaciclib jostling for second place in the market…”

Flera Intressanta Nyheter Under Årets ASCO-konferens - Redeye, June 5, 2017
“I en sammanställning av EP Vantage så framkommer det att hela 765 kombinationsstudier med PD-1/PD-L1-hämmare pågår och fler tillkommer kontinuerligt. Merck leder sammanställningen med 268 pågående studier med Keytruda, knappt före Bristol-Myers Squibbs Opdivo som är inblandad i 242 studier…”

Look back at pharma news to June 2 - The Pharma Letter, June 4, 2017
“Johnson & Johnson has placed a $50 million bet that pills are the next big development in inflammatory bowel disease, noted EP Vantage, the editorial arm of the Evaluate group…”

UPDATE: Cancer drug prices could double or triple thanks to this popular but unproven drug trend - MarketWatch, June 3, 2017
“Arguably, it has already reached fever pitch: There are nearly 800 ongoing and completed trials, according to a search of the federal database of clinical studies, up from about 200 such studies in the fall of 2015, according to a new EP Vantage/ Evaluate Ltd. report (http://info.evaluategroup.com/rs/607-YGS-364/images/epv-pdct17.pdf)...”

Plenty Can Go Right for Bristol-Myers - Dow Jones Newswires, June 2, 2017
“More than 240 clinical trials are under way across the industry that use Opdivo in combination with another drug, according to research firm EvaluatePharma…”

Teva On Track To File Migraine Blockbuster - Pharmaphorum, June 2, 2017
“According to EvaluatePharma, analysts rate fremanezumab highest among this class of drugs, forecasting sales in excess of $1 billion by 2022…”

In Quattro Per Strattera (Eli Lilly) - Daily Health Industry, June 1, 2017
“Ora però, secondo Evaluate Pharma, per il farmaco è prevista una rapida discesa a 13 milioni di dollari entro il 2022…”

Checkpoint Combos For Cancer Are All The Rage As Trial Sponsors Line Up Hundreds Of New Studies - Report - Endpoints, June 1, 2017
“Now EP Vantage has tallied the whole score on these combo trials, not coincidentally just ahead of ASCO, and found a stunning 765 combination studies listed on clinicaltrials.gov…”

Grail’s $1 Billion Guess on the Good - Tech2, June 2017
“Grail has raised $1.1 billion, a sum that places it among the many prime three most closely funded personal biotech corporations, in keeping with EvaluatePharma…”

Симджепи»: Альтернатива «Эпипен» - Chemrar, June 2017
“«Майлан» годами зарабатывала сумасшедшие деньги на копеечном эпинефрине: в 2016 году продажи «ЭпиПен» составили, согласно подсчетам EvaluatePharma, 1,18 млрд долларов. Маржа прибыли на автоинъекторе, производство которого обходится не более чем в 20 долларов за пару, постоянно увеличивалась, учитывая, ничем необоснованный рост розничной стоимости (с 100 до 600 долларов) за комплект из пары штук «ЭпиПен»…”

No Price Pressure on Orphan Drugs (Yet) - Managed Care Magazine, June 2017
“That growth rate is twice as fast as the expected increase in sales of all other prescription medicines, according to EvaluatePharma…”

Drugmakers May Lose $390B In Sales Over 5 Years – Investopedia - Taste Upgrade, June 2017
“EvaluatePharma, a division of health care market intelligence firm Evaluate Group LTD., has gash its global revenue projections for drugmakers by approximately $390 billion over the period from 2017 to 2022, according to the Financial Times….”

Sanofi Veut Devenir Un Champion De La Bioproduction De medicaments - Pharmelis, June 2017
“Issu du monde de la chimie, Sanofi a d’abord tardé dans les années 2000 à prendre la mesure du virage des biotechnologies dans le secteur pharmaceutique, qui pourrait représenter 29% du marché mondial en 2022, contre 17% en 2008, selon une étude d’Evaluate Pharma…”

Ситуация В США Повлияет На Мировые Объемы Продаж ЛС - IPM, June 2017
“В Evaluate Pharma подсчитали, что глобальные продажи ЛС в 2022 году составят 1,06 трлн долларов, а не 1,12 трлн долларов, как прогнозировалось еще год назад. Это впервые за 10 лет, когда эксперты пересматривают свои прогнозы в сторону понижения…”

США: Снижение Объема Продаж ЛС - mity.kz, June 2017
“В Evaluate Pharma подсчитали, что глобальные продажи ЛС в 2022 году составят 1,06 трлн долларов, а не 1,12 трлн долларов, как прогнозировалось еще год назад…”

Global Drug Sales Forecasts Fall For Next Five Years - HealthPopuli, June 2017
“Total prescription drug sales have been trimmed, based on calculations of EvaluatePharma which forecasts a $390 bn drop in revenues between 2017 and 2022…”

Prescribed Reading: Combos to take center stage at ASCO - BioPharma Dive, June 2017
“According to a recent report released by EP Vantage, immuno-therapy combos are skyrocketing —the number of combo trials has gone from 215 in 2015 to 765 and rising, currently. …”

Amputationsfare Fra Diabetesmiddel Er Enkeltstående - Medwatch.dk, June 2017
“Der har siden været en bekymring over, om problemet også ses for andre lægemidler i samme klasse. Men den frygt bliver nu manet til jorden af en ny analyse. Det skriver EP Vantage…”

 May 2017

Large acquisitions to expand into the US market. The sense of urgency a major generic maker holds. (Sawai) - Toyokeizai, May 13, 2017 

Ads, Not Research, Can Create Pharma Best-SellersP&T Community, May 31, 2017
“Nuedexta’s sales rose from approximately $37 million in 2012 to $218 million last year, according to EvaluatePharma, which tracks pharmaceutical industry pricing and markets…”

Why Drugs Like These For ‘Orphan’ Diseases Are A Booming Business With Colossal Costs For Patients - Globe And Mail, May 29, 2017
“EvaluatePharma, a U.S. company that analyzes the pharmaceutical and biotechnology sectors, predicts that orphan-drug sales will grow by 11 per cent a year over the next five years, twice the rate of conventional prescription drugs…”

Look Back At Pharma News To May 26 - The Pharma Letter, May 28, 2017
“The first case of a rare brain infection with Roche’s multiple sclerosis therapy Ocrevus should not cause too much alarm, with analysts putting it down to the patient's previous long-term treatment with Tysabri, stated EP Vantage, the editorial arm of the Evaluate group…”

Do Acid-Reducing PPIs Cause Kidney Damage? - Righting Injustice, May 25, 2017
“Many patients continue on PPI treatment for years, inflating profits for pharmaceutical companies with many billions of dollars of sales a year, according to commercial intelligence firm EvaluatePharma…”

Amgen’s Osteoporosis Med Almost A Home Run In Latest Trial; Fate Now Murky On Heart Safety - Monday Morning, May 24, 2017
“The drug was expected to exceed Thomson Reuters’ forecast and have sales of $917 million in 2022, according to consensus forecasts from EvaluatePharma…”

When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs - Bloomberg, May 24, 2017
“Globally, sales of orphan drugs are expected almost to double, to $209 billion, by 2022, based on numbers gathered by Evaluate Ltd., a life-sciences consulting company…”

Merck Gets Booster from Chinese HPV Vaccine Approval - Caixin, May 24, 2017
“For now, GSK and Merck are the only developers of the vaccine, although Merck dominates the global HPV vaccine market at a 94% share, according to research firm Evaluate Pharma...”

TOP15 дженериковых компаний по объему продаж в 2016 г. - Pharmclub, May 24, 2017
“В 2016 г. компания успешно завершила сделку по приобретению дженерикового бизнеса у ирландской Allergan за 40,5 млрд долл. Это крупнейшая сделка за всю историю дженериковой отрасли. По мнению экспертов Evaluate Pharma, она еще долго будет оказывать влияние на всю мировую индустрию дженериков…”

Feu vert américain pour Sanofi dans la polyarthrite - Les Echos, May 23, 2017
Article behind paywall.

Merck's Gardasil preps for head-to-head with GlaxoSmithKline’s Cervarix in China, with big sales targets ahead - Fierce Biotech, May 23, 2017
“The Gardasil family reeled in $2.17 billion in 2016 sales for Merck, and life science commercial intelligence firm Evaluate's most recent estimate in April for Gardasil's 2022 sales was around $2.07 billion, slightly downward from its previous forecast but would still place the vaccine as the second-best-selling vaccine product around the world…”

Sanofi Lance Un Nouveau Blockbuster Potential - La Tribune, May 23, 2017
“Le sarilumab pourrait ainsi tirer son épingle du jeu et atteindre 1,8 milliard de dollars de chiffre d'affaires d'ici à 2020, estime le cabinet de conseil Evaluate Pharma…”

Nanofluidic device for continuous multiparameter quality assurance of biologics - Nature Nanotechnology, May 22, 2017
Article is behind paywall.

Estas Son Las 10 Empresas Farmacéuticas Más Destacadas En El Mundo - Merca20, May 19, 2017
“Sólo los ingresos de las dos compañías farmacéuticas más destacadas en el mundo, superan los 100 mil millones de dólares, según datos de EP Vantage y Evaluate, proyectados por Statista…”

J&J Showcases Its 10 Blockbuster Prospects - Pharmaphorum, May 18, 2017
“Analysts EP Vantage currently predict that J&J will stand fifth in the overall pharma market by revenues in 2022….”

Shire Ltd.'s $6 Billion Bet On Drug For Hereditary Angioedema Pays Off With Stellar Phase III Data Talkmarkets, May 18, 2017
“Many analysts believe that Shire...is on a short path to blockbuster revenue. Shire itself set a goal of $2 billion in peak sales for this drug and EvaluatePharma recently picked it as a top-10 orphan drug bound for a booming market with 6-figure price tags…”

Farmaci, Amazon Si Sta Preparando A Entrare Nel Business Delle Vendite - RIF Day, May 18, 2017
“Ma l’indizio più probante di tutti è quello già anticipato in premessa: il mercato del farmaco, con i suoi 4 miliardi  su scala globale, è uno dei più ricchi al mondo e presenta prospettive sempre migliori, atteso che l’outlook di Evaluate Pharma (una delle più autorevoli società di ricerche su questo mercato a livello mondiale) prevede che nel 2020 le vendite mondiali di medicine toccheranno per la prima volta la fatidica soglia dei mille miliardi di dollari, ovvero circa 200 in più del mercato attuale…”

Shire’s Multibillion-Dollar Gamble On Lanadelumab Pays Off With Stellar Phiii Data, Quick Marketing Application - Endpoints, May 18, 2017
“And EvaluatePharma recently picked it as a top-10 orphan drug bound for a booming market with 6-figure price tags…”

Fast review for Bayer’s copanlisib in lymphoma - Pharmaphorum, May 17, 2017
“Evaluate Pharma has predicted sales of around $262 million for copanlisib by 2022, as Johnson & Johnson’s BTK inhibitor Imbruvica (ibrutinib) is proving popular with prescribers, as is Roche’s anti-CD20 Gazyvaro (obinutuzumab)….”

Do Best-Selling Drugs That Calm Stomachs Damage Kidneys? The Answer’s Unclear. - Kaiser Health News, May 17, 2017
“And it’s not uncommon for patients to take the heartburn pills for years, even though their labels recommend limiting treatment to a few weeks or a few months. The result has been sales worth many billions of dollars a year for pharmaceutical companies, according to commercial intelligence firm EvaluatePharma…”

Farmaci: In USA Vincono I Generici. Teva, Mylan E Novartis Sul Podio 2016 - Daily Health Industry, May 17, 2017
“Il generico è vincente negli USA, nonostante la questione prezzi. Teva, Mylan e Novartis (Sandoz) sono infatti le tre aziende che – secondo Evaluate Pharma – salgono sul podio a stelle e strisce per i fatturati 2016…”

Generici, chi ha venduto di più nel 2016? - Pharmastar, May 17, 2017
“Di recente, la società Evaluate Pharma ha messo a punto la classifica dei 15 maggiori produttori mondiali di generici. I dati di vendita utilizzati per mettere a punto la classifica sono stati compilati basandosi sull’anno fiscale delle aziende…”

La llegada de los biosimilares oncológicos, nuevo reto para los sistemas sanitarios - ElGlobal.net, May 17, 2017
“Para 2022 se estima que los fármacos oncológicos alcanzarán el 16,3 por ciento del total del mercado farmacéutico, superando los 190.000 millones de dólares, según el último informe publicado por la consultora Evaluate Pharma….”

Thermo Fisher's $7.2 Billion Buy of Patheon: The Implications for the CDMO Market - DCAT Connect, May 17, 2017
“The outsourcing of product development by the pharmaceutical industry is an important driver in the future combined company. In 2015, the pharmaceutical industry spent approximately $141.0 billion on formulation, development and manufacturing, according to Evaluate Pharma, and approximately $40.0 billion was expected to be outsourced to CDMOs in 2016, according to Root Analysis, as cited by Patheon in its 2016 annual report…”

Overwrought Marketing? Ads, Not Research, Create Some Pharma Best-Sellers - Kaiser Health News, May 16, 2017
“Nuedexta’s sales have risen from about $37 million in 2012 to $218 million last year, according to EvaluatePharma, which tracks pharmaceutical industry pricing and markets…”

The Top 15 Generic Drugmakers By 2016 Revenue - Fierce Biotech, May 16, 2017
“Trailing those two companies was Novartis, whose Sandoz unit tallied $9 billion in off-brand sales for the year, according to life science commercial intelligence firm Evaluate…”

Data Keeps Lilly in Race for New Migraine Treatment - Pharmaphorum, May 16, 2017
“According to Evaluate Pharma, Teva’s TEV-48125 is the most fancied by analysts, who forecast sales of just over $1 billion a year in 2022, with Alder’s eptinezumab expected to be not far behind…”

Biotechnologiím Patří Budoucnost - Finlord, May 16, 2017
“Jak ukazují statistiky EvaluatePharma, tak farmaceutický průmysl má obrovský potenciál do budoucnosti…”

Co-Pay Support Orgs Rank High Among Largest U.S. Charities – Politico, May 15, 2017
“This could lead to an FDA decision to pull the drug from the market. More from EP Vantage here…”

Panel Woes For Puma And Statistical Uncertainties For Emmaus - Seeking Alpha - Immortality Medicine, May 15, 2017
“Neratinib sales are forecast to reach $809m by 2022, according to sellside consensus from EvaluatePharma, but just over a year ago these sat at $2bn. Neratinib’s PDUFA date is set for July; a strong benefit with Perjeta could be hard for the FDA to ignore…”

Xarelto Legal Representative - Munation, May 15, 2017
“In its World Sneak peek, EvaluatePharma approximated that Xarelto will generate 3.7 billion UNITED STATE dollars in sales by 2018, making it the 19th very successful medication on the planet if these estimates prove true. Clients who assert to have experienced complications from the use of this medicine have actually filed Xarelto legal actions versus Janssen Pharmaceuticals and Bayer Healthcare with the help of a Xarelto attorney…”

Co-Pay Support Orgs Rank High Among Largest U.S. Charities - Politico, May 15, 2017
“This could lead to an FDA decision to pull the drug from the market. More from EP Vantage here…”

Patent Loss in Pharma - Tefen, May 15, 2017
“According to EvaluatePharma, Pharma companies stand to lose between $19-34 B due to patent expiry in 2017 alone. In the graph, you can see the history and the future trend for the global prescription drug market…”

America’s Criminal-Minded Drug Companies -  Here We Go Again - The New York Crank, May 15, 2017
“The market has proved lucrative. Nuedexta’s sales rose to $218 million last year from about $37 million in 2012, according to EvaluatePharma, which tracks pharmaceutical pricing and markets…”

How A Drug To Treat Crying Sent Sales Soaring - Pharmacist.Com, May 15, 2017
“The market has proved lucrative. The drug's sales rose to $218 million last year from about $37 million in 2012, according to EvaluatePharma…” more…
*Also duplicated in New York Times

Air Cargo Pharma Demand To Surge, But Industry Faces Challenges Ahead - Air Cargo Weekly, May 13, 2017
“And he expects the growth to continue, after highlighting to statistics from IMS Health and Evaluate Pharma that show biopharma logistics spend would reach US$93 billion in 2020 compared with $78 billion in 2016…”

Merck-Middel Scorer Ny Frontlinje-Godkendelse I Lungekræft - Medwatch, May 11, 2017
Article behind paywall.

Farmacie: Léky Na Předpis Jsou Zlatý Důl - Finlord, May 11, 2017
“Farmaceutický průmysl by měl růst dle údajů EvaluatePharma o 6,3 % ročně a měl by dosáhnout 1,2 bilionu USD do roku 2022…”

Pharmaceutical Cold Chain Logistics is a $13.4-Billion Global Industry - Q Products and Services, May 10, 2017
“ That fraction of approved drugs is then compared to measures of overall pharma sales (from organizations like IMS Health and Evaluate Pharma), and overall pharma logistics spend and volumes. …”

Focus on Rare Diseases - PMLive, May 10, 2017
“* EvaluatePharma Orphan Drug Report 2015…”

New Drugs For Not-So-Rare Diseases - Raconteur (Sunday Times insert), May 10, 2017
“Breakthroughs are being made at a time when blockbuster drugs are coming off patent, forcing pharmaceutical companies to explore new revenue streams. Evaluate Pharma, the life sciences intelligence firm, estimates that orphan sales hit $114 billion in 2016, a 12 per cent increase over 2015…”

Pharmaceutical cold chain logistics is a $13.4-billion global industry - Pharmaceutical Commerce, May 10, 2017
“That fraction of approved drugs is then compared to measures of overall pharma sales (from organizations like IMS Health and Evaluate Pharma), and overall pharma logistics spend and volumes…”

Mitsubishi Bags Als Approval Without Radical Benefit - Bullfax, May 9, 2017
“EP Vantage submits:The list of unpartnered amyotrophic lateral sclerosis (ALS) treatments just got smaller. Biogen Idec (BIIB) has snapped up the phase III-ready neuroprotective drug KNS-760704 for $20m in cash and a $60m stake in privately-held Knopp Neurosciences, allowing the partners to advance the compound into pivotal trials in the first half of next year…”

Kite Shares Sink After Death In CAR-T Trial - Pharmaphorum, May 9, 2017
“Analyst Evaluate Pharma has rated KTE-019 as the most valuable rare disease treatment in the pharma pipeline, with the potential for peak annual sales of $7.9 billion. Evaluate predicts peak sales for Novartis’ therapy of $4.7 billion…”

Investors Spooked By Kite CAR-T Death, But Biotech Remains Confident - Fiercebiotech, May 8, 2017
“As EvaluatePharma put it: “While patient numbers are far too small to draw firm conclusions, an uncomfortable fact is that KTE-C19 is an extremely similar CAR construct to JCAR015, differing only in the binding region it uses. The precise cause of cerebral edema with CAR-T is not understood, but it had surprised some that none had previously been seen with KTE-C19, given its similarity with JCAR015…”

Look Back At Pharma News To May 5 - The Pharma Letter, May 7, 2017
“The best-case scenario for Lundbeck and Otsuka following mixed clinical results with Rexulti in Alzheimer’s disease agitation may very well be that the US Food and Drug Administration will ask for a third trial to confirm that both the primary and secondary endpoints can be met in a single test, according to EP Vantage, the editorial arm of the Evaluate group…”

Biotekaktie Stiger Kraftigt Efter Vellykket Diabetesstudie - Medwatch, May 5, 2017
“Et fransk biotekselskab så torsdag sin aktie stige med op til 40 pct. i kølvandet på et vellykket fase 2b-studie med ny type diabetesbehandling. EP Vantage mener, at selskabet kunne være et interessant opkøbsmål for Novo Nordisk, som ”har brug for nyt blod…”

Internationales Drehkreuz Miami für Pharma-Luftfracht - Chemanager, May 4, 2017
“Das Marktforschungsunternehmen Evaluate Pharma prognostiziert der weltweiten Pharmaindustrie ein jährliches Wachstum von 6,3%. Bis 2022 wird sie einen Gesamtwert von 1,12 Bill. USD erreichen…”

Regeneron confident despite lackluster Q1 earnings - Times Union, May 4, 2017
“The first-of-its-kind treatment is expected to be among the most lucrative pharmaceutical launches of the year, with annual revenues potentially topping $4.6 billion by 2022, according to EvaluatePharma, a biotech research group…”

Three new board bio pharmaceutical fine molecular industry four potential stocks - Moxi, May 3, 2017
“According to EvaluatePharma forecasts, the global biopharmaceutical market will continue to maintain rapid growth in the future, 2014-2020 CAGR of about 10.1%, and in 2020 reached $287 billion 140 million…”

Самые Высокодоходные Компании Мирового Фармрынка За 2016 год - Lekoboz.ru, May 2, 2017
“Согласно прогнозу компании «EvaluatePharma», этот препарат в 2022 г. займет 3-е место в рейтинге самых продаваемых блокбастеров для лечения онкологических заболеваний в мире с прогнозируемым доходом от продаж на уровне 8,29 млрд дол…”

Is this “ask your doctor” advertisement educational or overly emotional? - Physicians News Digest, May 2017
“Still, the market has proved lucrative. Nuedexta’s sales have risen from about $37 million in 2012 to $218 million last year, according to EvaluatePharma, which tracks pharmaceutical industry pricing and markets…”

The Growth of Orphan Drugs - DDNews, May 2017
“Seven of the top 10 companies by orphan drug sales are global industry players,” said Lisa Urquhart, EP Vantage editor and report contributor…”

DTC Case Study: Nuedexta - World of DTC Marketing.com, May 2017
“Nuedexta’s sales rose to $218 million last year from about $37 million in 2012, according to EvaluatePharma, which tracks pharmaceutical pricing and markets…”

Dishman Pharmaceuticals and Chemicals Ltd (Merged) Management Discussions. - India Info Online, May 2017
“Further, the Evaluate Pharma World Preview 2015, Outlook to 2020 report, predicts that by 2020, about 9 of the 10 best-selling drugs (by revenue) in the United States will be specialty drugs, compared with 7 in 2014…”

New York State Wants Its Prescription Drug Money Back — Or Else - Smart Aging, May 2017
“The result has been sales worth many billions of dollars a year for pharmaceutical companies, according to commercial intelligence firm EvaluatePharma…”

Кризис И Ценовое Регулирование Менее Всего Затрагивают Производителей Дженериков - Sojuzpharma.Ru, May 2017
“В 2016 году Teva закрыла крупнейшую в отрасли сделку – приобрела за $40,5 млрд дженериковый бизнес у ирландской Allergan. Эта сделка будет долгие годы оказывать влияние на мировую дженериковую промышленность, считает аналитическая фирма Evaluate Pharma…”

Top-15 Дженериковых Компаний По Объему Продаж В 2016 Года - Farmsouz, May 2017
“Эта сделка будет долгие годы оказывать влияние на мировую дженериковую промышленность, считает аналитическая фирма Evaluate Pharma…”

Патентный обвал в мировой фармацевтике - PharmClub, May 2017
“Первая волна патентного обвала захлестнула фармотрасль в 2012 г. По оценке EvaluatePharma, патентную защиту тогда потеряли оригинальные препараты с общим объемом продаж 55 млрд долл…”

Pharmapills Puntata N. 10. La Classifica Delle 15 Maggiori Aziende Di Biosimilari Secondo Evaluate Pharma - Carriere Farmaceutico, May 2017
“Farmaci generici: Evaluate Pharma ha proposto la classifica dei 15 maggiori produttori mondiali…”

 April 2017

Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda - MarketInsider, April 30, 2017
“According to market research firm EvaluatePharma, Kevzara could garner peak sales of $1.8 billion by 2020…”

Kaneka increases raw materials for biopharmaceuticals, and invests 5 billion yen for production for Europe and US pharmaceutical companies - Nikkei, April 24, 2017

Самые высокодоходные компании мирового фармрынка за 2016 год - GMP News, April 28, 2017
“ Согласно прогнозу компании «EvaluatePharma», этот препарат в 2022 г. займет 3-е место в рейтинге самых продаваемых блокбастеров для лечения онкологических заболеваний в мире с прогнозируемым доходом от продаж на уровне 8,29 млрд дол…”


Regeneron's Eylea success makes it 'uniquely exposed' to Medicare payment shift - FiercePharma, April 27, 2017
“According to a new report from EvaluatePharma’s EP Vantage, the U.S. health program spends more on Regeneron’s highly successful eye treatment than any other drug injected at doctors’ offices…"


Pharma launch challenges will only get worse - Tribeca Knowledge, April 27, 2017
“For the top 10 medicines in the US last year, the average annual cost per patient for an orphan drug was $140,443 compared with $27,756 for a non-orphan product, notes a report by Evaluate Pharma…”


FDA Drug Approvals up Sharply in Q1 - Chemanager, April 24, 2017
“After a major slowdown in 2016, new drug approvals by the US Food and Drug Administration rose sharply in the first quarter of 2017, according to a report by EP Vantage. Up to mid-April, the authority had approved more new drugs than during the same quarter of during the past six years…”

Look back at pharma news to Apr 21 - The Pharma Letter, April 23, 2017
“Not putting all your eggs in one basket has clear benefits, said EP Vantage, the editorial arm of the Evaluate group discussing new data on Ultragenyx’ burosumab…”

18 Drugs To Lose Patents In 2017; Could Jeopardize $26.5B For Big Pharma - TalkMarkets, April 22, 2017
“EvaluatePharma has reported that $55 billion in total drug sales lost patent protection that year…”

Fujifilm Corporation, reinforcing the market to biopharmaceuticals in the US and UK, and 14-billion-yen investment on contract company - Nikkei, April 18, 2017

Making The Cut - AJP, April 16, 2017
“However, analysts are still predicting a range of new ‘blockbuster’ drug launches. Heading the list, according to EP Vantage’s 2017 preview, which ranks the year’s rollouts by 2022 sales, is Ocrevus (ocrelizumab), a multiple sclerosis drug from Roche…”

Best Ms Drug - New York City High Tech News, April 15, 2017
“At the top of the list, according to EP Vantage’s 2017 preview, which ranks the year’s rollouts by 2022 sales, is Ocrevus (ocrelizumab), the Roche multiple sclerosis drug that’s promising to shake things up in more ways than one...”


Honestly, Not Such a Good Friday - My Cancer Journey, April 15, 2017
“In this regard, in an interview with EP Vantage earlier this month, Luciano Rossetti, Merck KGaA’s head of R&D, told EP Vantage that M7824 is “the most exciting clinical asset in our pipeline right now” adding that it has yielded “spectacular” early data…”

Not sold: FDA demands more data on Eli Lilly’s rheumatoid arthritis drug - MedCity News, April 14, 2017
“Despite the cluster of therapies now available for RA, EvaluatePharma had projected sales of Olumiant to reach nearly $1.8 billion per year by 2022…”

After attracting star CEO Hung, Axovant looks to raise $125m - Pharmaphorum, April 12, 2017
“However even a relatively modest success could open up a huge market for Axovant – last year analysts EP Vantage ranked the molecule as the most valuable unpartnered asset, estimating its net present value as $5.2 billion...”

Neurocrine nabs Ingrezza OK to kick-start tardive dyskinesia market, with Teva waiting in the wings - FiercePharma, April 12, 2017
“EP Vantage, for one, predicts that launch has blockbuster potential, pegging the med’s 2022 sales at $1.3 billion….”


Nothing’s Gonna Stop Neurocrine Biosciences Now: Shares Jumped on FDA Approval of the First and Only Drug to Treat Tardive Dyskinesia for Adults - BioSpace, April 12, 2017
“EvaluatePharma has also projected blockbuster status…”

Nine blockbuster drugs to watch are making their debut, aiming at a $16B prize in 2021 - Endpoints, April 11, 2017
“EvaluatePharma put together their list of top drugs in the pipeline, and came up with 15 prospective blockbusters…"

Neurocrine Bioscience Receives FDA Approval For Ingrezza For Treatment Of TD; Stock Jumps 19% - TalkMarkets, April 11, 2017
“EvaluatePharma has also tracked a blockbuster future for this drug as well, designed to treat involuntary movements spurred by the prolonged use of antipsychotics. Huntington’s chorea is a related condition involving involuntary twisting and writhing….”

Continua la crescita del mercato dei farmaci orfani - Notizaro Chimico Farmaceutico, April 11, 2017
“Quest’anno abbiamo di nuovo evidenziato che sono le big pharma che dominano il settore”, ha spiegato l’analista Lisa Urquhart a proposito dei risultati del quarto rapporto “EvaluatePharma Orphan Drug Report 2017”, secondo il quale sette delle dieci maggiori aziende del settore per volume di vendita sono grandi player farmaceutici globali…”

MedNess: FDA approvals,rejections, M&A and more… - Club SciWri, April 10, 2017
“According to EvaluatePharma, Zejula is one of the top drug launches of 2017 with 2022 sales expectations of $1.9 billion…”

5 trends shaping rare disease drug development - BioPharma Dive, April 10, 2017
“As more rare disease medicines make it to market, worldwide sales of the orphan drugs have grown rapidly, increasing at a faster rate than sales of non-orphans according to Evaluate Pharma, a life sciences intelligence firm…”

Why drugs like these for ‘orphan’ diseases are a booming business with colossal costs for patients - The Globe and Mail, April 8, 2017
“EvaluatePharma, a U.S. company that analyzes the pharmaceutical and biotechnology sectors, predicts that orphan-drug sales will grow by 11 per cent a year over the next five years, twice the rate of conventional prescription drugs…”

Look back at pharma news to Apr 7 - The Pharma Letter, April 8, 2017
“The move by Japan’s largest drugmaker, Astellas Pharma  to buy Ogeda seems more driven by a wish to own a particular asset than by expansion plans, commented EP Vantage, the editorial arm of the Evaluate group…”
 
6 trends shaking the pharmaceutical market - The Network Effect, April 7, 2017
 “According to EvaluatePharma, “World Preview 2018,” between 2012 and 2018, generic erosion was projected to wipe out about $148 billion in pharmaceutical revenues…”

The Bay Area Pharma Stock Investors Could Buy and Hold for the Next 20 Years - BioSpace, April 7, 2017
“Because BioMarin focuses on rare and ultra-rare diseases, the prices—and hence the margins—on their drugs are sky high. Budwell points out that EvaluatePharma’s most recent industry report indicates that orphan drugs will have 20 percent of the total prescription market by 2022. And BioMarin is one of the top orphan drugmakers. ..”

3 Stocks We'd Buy and Hold for the Next 20 Years - The Motley Fool, April 6, 2017
“In fact, EvaluatePharma's latest industry report has orphan drugs grabbing over 20% of the total prescription drug market by 2022…”

*Also in Madison.com 

Changing Expectations in the Pharma Outsourcing Market - Interphex Blog, April 6, 2017
“The global pharmaceutical market is currently expanding at a healthy compound annual growth rate (CAGR) of 6.3% according to EvaluatePharma…”

Could the Ranbaxy whistleblower head the FDA office in India?; Reprieve for GSK as Mylan’s Advair generic gets delayed - PharmaCompass, April 6, 2017
“EvaluatePharma has pegged consensus forecasts of revenue for 2022 at US $ 4 billion for this therapy. Dupixent is expected to land about a billion dollars behind Ocrevus…”

By Engaging Payers Before Setting Price, One Drug Company Wins Praise Despite $37K-A-Year Cost - KHN, April 5, 2017
“Analysts expect both drugs could top $4 billion in annual revenues by 2022, according to a recent analysis from the forecasting firm Evaluate Pharma…”

FDA approves Teva’s Huntington’s Disease drug - Pharmaphorum, April 5, 2017
“Analysts Evaluate Pharma predict sales of more than $3.4 billion in 2022, making this an important drug for the Israel-based pharma as its big-selling Copaxone multiple sclerosis drug comes under threat from generics…”

Have we finally turned a corner with drug pricing? - MedCity News, April 4, 2017
“Based on EvaluatePharma’s predictions, Ocrevus and Dupixent will be the highest grossing drugs to enter the market in 2017. The pricing on those drugs matters…”


Replicel (Rp.V) Targeting Multiple Billion Dollar Markets With Autologous Cell Therapies - SCR, April 4, 2017
“The skin rejuvenation market is enormous. Botox®, which is used to treat facial wrinkles, had 2015 worldwide sales of $2.8 billion in 2015 (EvaluatePharma)…”

Firms inject funds into biopharmaceuticals - The Japan News, April 4, 2017
“The British research firm EvaluatePharma estimates that the global market for biopharmaceuticals will reach $200 billion in 2016, about 1.4 times larger than five years ago…”


Behind Rare Disease Day 2017 - Pharmafile, April 3, 2017
“Some of the most expensive treatments offered in the world are those that treat rare diseases; according to a report on orphan drugs by EvaluatePharma, the average price tag in the US comes in at $111,820 per year compared with $23,331 for more regular medicines…”

Kite keeps pressure on Novartis with CAR-T filing - Pharmaphorum, April 3, 2017
“According to analyst Evaluate Pharma, axicabtagene ciloleucel is the most valuable orphan drug in the pharma pipeline…”


Brief: Report: Market Share Of Orphan Drugs Could Top 20 Percent Of Global Market By 2022 - IP Watch, April 3, 2017
“EvaluatePharma, a company headquartered in London which provides consensus forecasting to the pharmaceutical and biotechnology industries, has released its Orphan Drug Report 2017…”

Pfizer keeps nose ahead of rivals with new Ibrance approval - PMLive, April 3, 2017
“EvaluatePharma analysts have suggested Ibrance will become a mega-blockbuster with sales of $6bn-plus in 2022, consigning its CDK4/6/rivals - still tipped for big sales - into a scrabble for second place…”

Newsmakers: Peter Soelkner - Contract Pharma, April 3, 2017
“According to the Evaluate Pharma, World Preview 2016, Outlook to 2022, from the period of September 2016 until 2022, sales volume in orphan drugs is expected to increase significantly, effectively doubling…”

Look back at pharma news week to Mar 31 - The Pharma Letter, April 2, 2017
“Roche now has the first approved drug for both the relapsing and primary progressive forms of multiple sclerosis in the shape of Ocrevus, noted EP Vantage, the editorial arm of the Evaluate group…”

Orphan Drug Surge Raises Regulatory and Development Challenges - Applied Clinical Trials, April 1, 2017
“Meanwhile, orphan drugs will account for more than 21% of worldwide brand-name prescription drug sales in 2022, up from 6% in 2000, according to an analysis by EvaluatePharma…”


Pharmapills puntata n.5. La crescita del mercato dei farmaci orfani secondo il report di EvaluatePharma - Carriera Nel Farmaceutico.com, April 2017
“Persone: Rino Rappuoli (GSK Vaccines), Pei-Yong Shi (Università del Texas di Galveston), Duncan M. Baird (Università di Cardiff), Lisa Urquhart (Evaluate Pharma), Kevin C. Gorman (Neurocrine Biosciences), Edward Cox (FDA), Andrea Fagiolini (Università di Siena)…”


I 10 FARMACI PIÙ ATTESI DEL 2017 - Farmivi, April 2017
“La società americana Evaluate Pharma ha stilato la classifica dei 10 farmaci che saranno lanciati nel corso del 2017 e che nel 2022  raggiungeranno i fatturati più elevati. E’ una previsione, si intende, ma fatta

da chi i conti li sa fare…”

КАК ЛЕКАРСТВА НОВОГО ПОКОЛЕНИЯ ИЗМЕНЯТ ГЛОБАЛЬНЫЙ РЫНОК ОНКОПРЕПАРАТОВ - Pharma.net.ua, April 2017
“По данным EvaluatePharma, ТОП-3 глобального рынка онкопрепаратов (L01 L02, по классификации ATC) в 2015 году был представлен блокбастерами Roche – Мабтерой (ритуксимаб), Герцептином (трастузумаб) и Авастином (бевацизумаб), впервые введенными в обращение в 1997, 1998 и 2004 годах соответственно и принесшими производителю в 2015 году около $20 млрд. В 2016 году этот расклад, если не брать в расчет выход аналогов этих препаратов, сохранился практически повсеместно. Но скоро все должно измениться…”

 March 2017

Automation: A more reliable and scalable way to process samples in the biopharmaceutical lab - Laboratory Focus, March 31, 2017
“In a September 2016 publication by EvaluatePharma 1, they estimated by 2022, biologic drugs will contribute 50 per cent of the top 100 pharmaceutical product sales…”

Дайджест / Фармацевтический рынок » Рынок орфанных препаратов: какие факторы обусловливают рост? - Clinical-Pharmacy.ru, March 28, 2017
“Так, согласно отчету «Orphan Drug Report 2017» аналитической компании «Evaluate Pharma», если по итогам 2016 г. лавры лидера мирового рынка по объему продаж орфанных препаратов в денежном выражении принадлежали компании «Novartis», то к 2022 г. на данном посту ее, вероятно, сменит компания «Celgene»…”

Farmaceutico: previsioni per il 2017 secondo il report di EP Vantage CRA Secrets, March 27, 2017
“Eppure, gli esperti di Evaluate Pharma, editoriale indipendente con sede a Londra, hanno elaborato un report che presenta le previsioni per il 2017 relative al settore delle industrie pharma e biotech…”

Look back at pharma news to Mar 24The Pharma Letter, March 25, 2017
“Drugmakers, regulators and legislators have put enormous effort towards bringing abuse-proof painkillers to market over the past decade or more, with little to show for it, noted EP Vantage, the editorial arm of the Evaluate group…”

La industria avisa de la llegada de una “ola de biosimilares oncológicos”El Global.net, March 24, 2017
“Para 2022 se estima que alcanzará el 16,3 por ciento del total del mercado farmacéutico, superando los 190.000 millones de dólares, según el último informe publicado por Evaluate Pharma…”

GAO to Investigate FDA's Orphan Drug Program Medscape, March 23, 2017
“The rare-disease drugs have become increasingly popular with pharmaceutical and biotech companies and are expected to comprise 21.4 percent of worldwide prescription sales by 2022, not including generics, according to consulting firm EvaluatePharma’s 2017 orphan drug report…”

Biogen-sejr er gode nyheder for Forward Pharma Medwatch, March 23, 2017
“Og det er gode nyheder for det danske biotekselskab Forward Pharma, skriver EP Vantage…”

U.S. government plans to probe orphan drug programSpectrum, March 23, 2017
“They are expected to constitute 21.4 percent of worldwide prescription sales by 2022, not including generics, according to consulting firm EvaluatePharma’s 2017 orphan drug report…”

Week Nine Just FineMy Cancer Journey, March 22, 2017
“ In this regard, in an interview with EP Vantage earlier this month, Luciano Rossetti, Merck KGaA’s head of R&D, told EP Vantage that M7824 is “the most exciting clinical asset in our pipeline right now” adding that it has yielded “spectacular” early data. You can read the full interview by clicking here…”

ATF V: Iniating Coverage of Antibe Therapeutics Inc.; Developing Next Generation NSAIDS Complemented By Tissue Regeneration Subsidiary Zacks, March 22, 2017
“NSAIDS comprise one of the largest drug classes worldwide, with estimated sales of both prescription and non-prescription drugs approaching $9 billion in 2016 (EvaluatePharma)…”

Exclusive: Three Hepatitis C Drugs from Foreign Pharmaceuticals Close to Approval, Sources Say Caixin, March 22, 2017
“Since 2013, DAAs have become very popular, and their global sales have jumped from $5 billion in 2013 to $24 billion in 2015, according to pharmaceutical and biotechnology research firm EvaluatePharma…”

Look back at pharma news to Mar 17 The Pharma Letter, March 19, 2017
“FDA approval of the second CDK4/6 inhibitor, Novartis’ breast cancer drug Kisqali, has set up a battle against the current incumbent, Pfizer’s Ibrance, commented EP Vantage, the editorial arm of the Evaluate group. ..”

Weesgeneesmiddelen in de lift Vereniging Innovatieve Geneesmiddelen, March 17, 2017
“De markt voor weesgeneesmiddelen zal de komende jaren flink groeien, zo blijkt uit het Orphan Drug Report 2017 van EvaluatePharma…”

Mylan deal with Roche clears path to biosimilar Herceptin launchPMLive, March 14, 2017
“Despite the competition, EvaluatePharma has suggested that Roche's blockbuster products will still be bringing in good revenues for the foreseeable future, as biosimilars do not tend to cause the steep declines on brands as traditional generics…”

Rollout of Regeneron's new eczema drug could be most lucrative of the year Times Union, March 13, 2017
“Barely three months into the year, analysts are predicting the company's pending Dupixent drug could be the most lucrative pharmaceutical launch of 2017, with annual revenues topping $4.6 billion by 2022, according to EvaluatePharma, a biotech research group…”

German Merck, flying under Street’s radar, gets no respect; but not for long Monday Morning, March 13, 2017
“Luciano Rossetti, the German group’s head of R&D, said the bispecific fusion protein, known only under the designation M7824, “is the most exciting clinical asset in our pipeline right now,” according to EP Vantage…” 

Pfizer wins 1st round with marketing exec accused of stealing launch plans Awesome Investors, March 13, 2017
“And it has other competitive rollouts underway; the drugmaker’s hot new breast cancer seller Ibrance is about to gain new competition from Novartis, whose LEE011 could rack up $1.6 billion by 2022, EP Vantage predicts…”

Supporting the Pharma Industry Small Business Growth Engine Pharma’s Almanac, March 8, 2017
“New Report Shows Orphan Drug Market to Reach $176 Billion by 2020. EvaluatePharma. 29 Oct. 2014. Web…”

Kraftig marknadstillväxt för särläkemedel 2017-2022 Biostock, March 8, 2017
“Det fastslår Evaluate Pharma i en ny analys. Särläkemedel eller orphan drugs, betecknar sådana läkemedel som kan behandla, förebeygga eller diagnosticera livshotande eller kroniskt försvagande sjukdomar och som drabbar högst 5 av 10 000 individer…”

EP Vantage Journalist Jacob Plieth Tweets: Hearing rumour that Morgan Stanley might advise $NVO on $GBT deal. Board has authorised $NVO CEO to bid up to $45. – Benzinga, March 8, 2017

EP Vantage's Plieth tweets rumor about Global Blood deal price - The Fly, March 8, 2017
“Jacon Plieth of EP Vantage tweeted, "Hearing rumour that Morgan Stanley might advise $NVO on $GBT deal. Board has authorised $NVO CEO to bid up to $45…”

Global orphan drugs market to reach $ 209 billion by 2022Cote Orphan, March 8, 2017
“Seven of the top 10 companies by orphan drug sales are global industry players”, said Lisa Urquhart, EP Vantage editor and report contributor...”

Roche breast cancer trial success could kill Puma’s rivalPharmaphorum, March 8, 2017
“But analysts have been unimpressed with the data for neratinib, and according to EP Vantage, an FDA advisory committee could deal the drug a “fatal blow”, assuming Roche chooses to announce the data at the American Society of Clinical Oncology conference in June…”

Global orphan drugs market to reach $ 209 billion by 2022Business Standard, March 7, 2017
“Worldwide orphan drug sales forecast to total $ 209 billion (growing at CAGR of 11.1 percent from 2017 to 2022); approximately double overall prescription market growth, according to Evaluate latest report ‘EvaluatePharma Orphan Drug Report 2017’. ..”

Why are Drug Prices for Rare Diseases on the Rise? HealthLine, March 6, 2017
“According to a report on orphan drugs by EvaluatePharma, the average annual cost for orphan drugs was $111,820, compared with $23,331 for mainstream drugs…”

Orphan Drug Market to Continue Steady Growth; Sales to Double Between 2016 and 2022 AJCN, March 6, 2017
“According to EvaluatePharma’s Orphan Drug Report 2017, insurers will continue to cover orphan drugs, which will drive continued growth of the market. Sales of orphan drugs are expected to double between 2016 and 2022. By 2022, worldwide orphan drug sales are expected to total $209 billion and orphan drugs are set to be 21.4% of brand-name prescription drugs..”

The market of rare disease drugsGoinpharma, March 5, 2017
“According to a recent report by EvaluatePharma, the drug market includes 4,000 orphan drugs approved since the 1980s, with more than 300 last year, and generates approximately $114bn…”

Look back at pharma news to Mar 3The Pharma Letter, March 5, 2017
“Also commenting on Merck, EP Vantage, the editorial arm of the Evaluate group, said Merck’s $2.9 billion impairment charge on uprifosbuvir proves what many have long suspected: that the company overpaid for Idenix, effectively spending $3.9 billion on an asset it now estimates is worth just $240 million…”

UPDATE: First Woman CEO of a Global Drug Maker starts at GSK today Labiotech, March 4, 2017
“According to an EP Vantage report, she will start at a salary dramatically lower than her fellow male CEOs did during their first years on the job. Shareholders have cited a lack of experience…”

Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report FierceBiotech, March 3, 2017
“The image of the plucky small biotech striving to develop treatments for the rare diseases largely ignored by big pharma is long gone,” EP Vantage editor and report contributor Lisa Urquhart said in a release accompanying the report. “Instead, this year we again find big pharma dominating the sector…”

Orphan Drugs IFPW, March 2, 2017
“Source: Edited excerpts from a report by Andreas Hadjivasiliou, an Analyst at EvaluatePharma, edited by Lisa Urquhart, Editor at EP Vantage and published by EvaluatePharma®…”

Orphan drugs will fuel pharma’s future – and a pricing pushback too Pharmaphorum, March 1, 2017
“Evaluate’s Orphan Drug Report 2017 forecasts that worldwide orphan drug sales will reach $209 billion in 2022, and will account for 21.4% of total prescription drug sales…”

Top 10 U.S. patent losses of 2017Ingenium, March 1, 2017
“To find the top U.S. patent losses for 2017, FiercePharma consulted life science commercial intelligence firm Evaluate and Drug Patent Watch, plus public securities filings, FDA records, court documents and other sources to navigate the often complicated story of intellectual property in pharmaceuticals…”

Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs PharmExec, March 1, 2017
“Highlights of the EvaluatePharma Orphan Drug Report 2017 include..”  

The top 10 orphan drugs in the late-stage pipeline Endpoints, March 1, 2017
“Every year, Evaluate crunches the numbers on the top prospects in the pipeline, and the company’s editorial arm EP Vantage includes it in their annual report on orphan drugs…”

Exponential growth expected in global medical device sector MediWorld Middle East, March 2017
“As the sector witnesses a ‘resurgence of small acquisitions’, global medical device and technology growth is to go up by 5 per cent or more annually until 2022, reaching around $530 million, market research firm Evaluate reveals…”

Rare Disease Trials: The Pros and Cons of Small Patient Groups MDGroup, March 2017
“According to EvaluatePharma, global sales of orphan drugs are forecast to grow by more than 11 per cent per year to $209bn in 2022…”

Составлен обзор глобального рынка орфанных препаратов и прогноз до 2022 г. – News.Sputnik.ru, March 2017
“Отнесение того или иного заболевания к категории редких (орфанных) зависит от числа страдающих от него пациентов, которое варьируется вразных странах, пишет EvaluatePharma…”

Pharmapills puntata n. 2. I farmaci che fattureranno di più nel 2017 Carriere Nel Farmaceutico March 2017
“Persone: Amy Brown (EP Vantage), Maurizio de Cicco (Roche), Andrea Agazzi (NMS Group), Romano Marabelli (Ministero della Salute), Dan L. Longo (Università di Harvard), Carmine Pinto (Aiom), Federica Meloni (Università di Pavia)…”

 February 2017

Orphan drugs attract rich returns for pharmaceuticals – Financial Times, February 28, 2017

According to a new report by research group EvaluatePharma, there have been nearly 4,000 orphan drug designations granted by regulators in the US since the early 1980s, with more than 300 last year alone."

Orphan drug market growing, despite high costs Manufacturing Chemist, February 28, 2017
“Median cost per patient for orphan drugs is 5.5 times higher than non-orphan drugs, according to “EvaluatePharma Orphan Drug 2017 Report…”

Small patient groups hinder progress of clinical trialsFT, February 28, 2017
“Global sales of orphan drugs are forecast to grow by more than 11 per cent per year until 2022 to $209bn, according to

research group EvaluatePharma…”

Orphan drug sales will outpace all other meds, thanks to high prices STAT News, February 28, 2017
“Based on worldwide orphan drug sales, seven of the 10 largest players are global companies, including Novartis, Roche, and AbbVie, not upstart biotechs, according to the analysis, which was conducted by EvaluatePharma, a market research firm…”

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016PMLive, February 28, 2017
Press release posted on site

Median cost per patient for orphan drugs is 5.5 times higher, report says The Pharma Letter, February 28, 2017
“The average US cost per patient per year for an orphan drug was $140,443 in 2016, compared with $27,756 for a non-orphan, according to the EvaluatePharma Orphan Drug 2017 Report…”

Las ventas de medicamentos huérfanos se duplicarán en los próximos cinco añosim farmacias, February 28, 2017
“La IV EvaluatePharma Orphan Drug Report reúne los análisis necesarios para entender cómo funciona y funcionará el mercado de medicamentos huérfanos desde 2017 y hasta 2022...”

Los medicamentos huérfanos, en torno al 22% del mercado total en 2022  - DiarioFarma, February 28, 2017
“Los datos de la consultora especializada Evaluate Pharma con respecto a la evolución de los medicamentos huérfanos son concluyentes. Y es que, pese al escaso peso que tienen en la actualidad sobre el mercado total de fármacos innovadores de prescripción, se espera que aglutinen en torno al 21,4% de éste en 2022, con unas ventas que podrían situarse en el entorno de los 209.000 millones de dólares y un crecimiento medio anual del 11,1%...”

Orphan drug sales will outpace all other meds, thanks to high pricesSTAT News, February 28, 2017
“Based on worldwide orphan drug sales, seven of the 10 largest players are global companies, including Novartis, Roche, and AbbVie, not upstart biotechs, according to the analysis, which was conducted by EvaluatePharma, a market research firm…”

These Were Big Pharma’s Biggest Winners and Losers in 2016Fortune, February 28, 2017
“Biopharma stocks endured a precipitous decline over the course of 2016. But some giants drug making giants made out far better than others, according to a new report based on data from analytics firm Evaluate…”

Look back at pharma news to Feb 24The Pharma Letter, February 26, 2017
Article behind paywall

‘Orphan drugs’ no lifeline if you can’t afford themSanta Fe New Mexican, February 26, 2017
“The top 100 orphan drugs in the U.S. cost an average of $111,820 a year per patient in 2014, according to a report by Evaluate Pharma, a market research firm…”

Patient death in phase 3 raises doubts about safety of Roche’s potential hemophilia blockbuster emicizumabFierceBiotech, February 24, 2017
“Emicizumab, also known as ACE910, is tipped to be a big seller for Roche—EvaluatePharma analysts predicted it will hit $1.4 billion in annual sales in 2022 last year—but the safety concerns could scuttle its attempt to unseat incumbents such as Shire…”

Какие лекарственные средства войдут в ТОП-10 в 2017 году?Pharm.reviews, February 24, 2017
“Компания EvaluatePharma опубликовала прогнозный рейтинг ТОП-10 препаратов по объему продаж в денежном выражении…”

These Were the 10 Biggest Pharmaceutical Deals of 2016 Fortune, February 24, 2017
“And that also had an effect on dealmaking, with a dearth of health care "megadeals" and a retrenchment in overall deal value, according to a new analysis by analytics firm Evaluate's EP Vantage arm…”

Healthcare Watch February 2017PM360, February 24, 2017
“Novo Nordisk’s once-weekly type 2 diabetes treatment semaglutide, is expected to be the most successful small-molecule drug launched in 2017, according to EvaluatePharma, a market intelligence firm that forecasts prescription drug sales…”

Top 10 patentów na leki, które wygasają w 2017 roku Polityka Zdrowotna, February 23, 2017
“Cialis (stosowany w leczeniu zaburzeń erekcji), którego producentem jest koncern Eli Lilly. W roku 2016 sprzedaż tego leku osiągnęła wartość 1,42 miliarda dolarów. Prognozy EvaluatePharma na rok 2022 wskazują spadek do 55 milionów dolarów…”

ТОП-10 ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ ПО ОБЪЕМУ ПРОДАЖ В 2017 ГОДУPharmanet.ua, February 23, 2017
“EvaluatePharma опубликовала прогнозный рейтинг ТОП-10 препаратов по объему продаж в денежном выражении. Эти препараты принесут фармкомпаниям-производителям наибольшую выручку от реализации в 2017 году…”

Five things for pharma marketers to know - MM&M, February 23, 2017
“EvaluatePharma estimates that Amgen's Enbrel, used to treat rheumatoid arthritis, costs nearly $45,000 for a year of treatment and Lilly's Forteo, an osteoporosis medicine, runs about $29,000 per year. (Boston Globe)…”

Gute Renditechancen Payoff, February 22, 2017
“Allerdings gibt es auch in Zukunft durchaus Potenzial bei ausgewählten Werten, zumal die renommierten Experten von EvaluatePharma für die verschreibungspflichtigen globalen Verkäufe bis 2022 Wachstumsraten von gut 6%

prognostizieren…”

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals  – Endpoints, February 22, 2017
“In a look back over a relatively quiet  year, EP Vantage, the editorial arm at Evaluate, concluded that 2016 may not have ended anywhere close to any of the records set during the boom, but I would add that the numbers reflect some considerable financial muscle that could be flexed in the year to come…”

Harvard Pilgrim expands use of novel drug purchasing deals Boston Globe, February 22, 2017
“Enbrel costs nearly $45,000 per patient per year in the United States, according to the research firm EvaluatePharma, while Forteo costs about $29,000 a year…”

Brevetti: ecco le scadenze USA del 2017 Daily Health Industry, February 22, 2017
“Nonostante l’azienda israeliana stia cercando di ritardare l’arrivo dei generici con battaglie legali, alla presentazione dei risultati del quarto trimestre del 2016 Teva ha previsto una perdita compresa tra 1 e 1,3 miliardi di dollari per Copaxone, con un eventuale arrivo dei generici sul mercato. Al secondo posto c’è Cialis, di Eli Lilly, che secondo EvaluatePharma potrebbe scendere da 1,42 miliardi di dollari incassati nel 2016 a 55 milioni di dollari nel 2022. Probabilmente le vendite resteranno alte quest’anno, ma già dal 2018 dovrebbero cominciare a calare…”

Top 10 U.S. patent losses of 2017 Fierce Biotech, February 21, 2017
“To find the top U.S. patent losses for 2017, FiercePharma consulted life science commercial intelligence firm Evaluate and Drug Patent Watch, plus public securities filings, FDA records, court documents and other sources to navigate the often complicated story of intellectual property in pharmaceuticals….”

Gilead snaps up Sarepta's priority review voucher for $125M BioPharma Dive, February 21, 2017
“Backing out other known costs from Gilead's estimates in that regulatory document, it is likely Gilead paid somewhere in the $200 million or below range for that second voucher, according to EP Vantage's Jacob Plieth…”

FDA APPROVES ONLY 22 NOVEL DRUGS FOR 2016. HERE IS THE TOP 10 Clinicubes, February 21, 2017
“According to EP Vantage’s 2017 preview, which has made the chart according to top sales estimates, the leader of the list is Roche’s Ocrevus (ocrelizumab)…”

Valeant, Alnylam & Juno shares took some of the biggest hits last year MedCity News, February 21, 2017
“The final tallies for 2016 – both the winners and the losers – were delivered Tuesday courtesy of EP Vantage, the editorial arm of life

Quel giro d’affari miliardario sulla ricerca dei farmaci orfani La Stampa, February 21, 2017
“Nel frattempo, come mostra l’Orphan drug report 2016 di Evaluate pharma, il mercato vola e raggiungerà i 182 miliardi di dollari nel 2022, marciando al ritmo del più 11,7% l’anno…”

Celgene to file potential MS blockbuster this yearPharmaphorum, February 20, 2017
“Analysts EP Vantage have predicted sales of around $4.4 billion by 2020…”

Pricing pressures in changing market landscapes: tapping the value nexusTotal Biopharma, February 21, 2017
“Evaluate Pharma projects that orphan drugs will represent more than 20.2% of global prescription sales by 2020 (excluding generics), compared with just 6.3% in 2000…”

Durvalumab Receives Breakthrough Therapy StatusBioPharm International, February 17. 2017
“EvaluatePharma predicts atezolizumab could receive FDA approval in 2016…”

El mercado oncológico liderará el sector hasta el 2022 Mirada Profesional, February 16, 2017
“Un informe de la consultora Evaluate Pharma ubica al mercado oncológico como el sector de mayor crecimiento hacia el próximo lustro. ..”

Ökat antal cancer- och särläkemedel de senaste 20 åren BioStock, February 15, 2017
“Ett bra exempel är världens mest inkomstbringande receptbelagda läkemedel, AbbVies Humira mot artrtit som enbart i USA drabbar 53 miljoner människor. Under 2014 sålde Humira för 11,8 miljarder dollar och 14 miljarder dollar året därpå. Evaluate Pharma förutspår att läkemedlet kommer inbringa 15,92 miljarder dollar år 2020…”

Senator launches investigation into FDA's orphan drug program - Advisory Board, February 15, 2017
“According to EvaluatePharma, orphan drugs currently represent seven of the 10 top-selling drugs, in terms of annual sales…”

ТОП-10 самых ожидаемых новых препаратов 2017 года Farmmafia, February 14, 2017
“EvaluatePharma опубликовала прогнозный рейтинг наиболее ожидаемых новых препаратов, лонч которых состоится в 2017 году. Эти препараты принесут фармкомпаниям-производителям наибольшую выручку от реализации в течение ближайших 5 лет…”

Darzalex var analytiker-darling i 2016 - Medwatch, February 14, 2017
Article behind paywall.

Can Roche's Herceptin-Perjeta combo expand yet again? Check the impending data FiercePharma, February 13, 2017
“EP Vantage noted early this year that an approval in that population would “substantially expand” the combo’s market…”

Therapeutic Antibodies to Track in 2017, Part IBioPharma International, February 13, 2017
“For 2017, life-science commercial intelligence firm Evaluate, in collaboration with BioPharm International, predicts that FDA may grant marketing approval to somewhere in the range of 8–16 antibody-based investigational candidates…”

Inmunoterapia bursátil contra el cancer El Economista, February 12, 2017
“En este sentido, Celgene es la que más atractivo guarda para los bancos de inversión. Según la consultora Evaluate Pharma, el mercado de la oncología crecerá anualmente un 12,5 por ciento hasta 2022, cuando se espera que las ventas alcancen los 190.000 millones de dólares…”

Sen. Grassley Opens Inquiry Into Orphan Drug Act RAPS, February 10, 2017
“According to data from EvaluatePharma, "7 of the top 10 projected worldwide best selling drugs in 2015 have an FDA-approved orphan indication..."

Pfizer stumbles to 4Q profit after rough year for Prevnar; what happened to industry leadership role?Monday Morning, February 9, 2017
“Now, as the key brand is expected to slow in the coming years, EvaluatePharma recently estimated that the company’s vaccines group would post an average sales increase of just 2% per year through 2022. Prevnar might gain new life in the US from a new indication in adults aged 18 to 49, granted by the FDA last year. That approval put Prevnar on tap for US adults 18 and older…”

LES DÉBOIRES DE 2016 VONT-ILS COÛTER CHER À SANOFI ?Societe, February 9, 2017
“Il pourrait générer 1,8 milliard de dollars de chiffre d'affaires d'ici à 2020 au total, d'après le cabinet de conseil Evaluate Pharma…”

Regeneron, Sanofi win reprieve from court ban on Praluent BioPharma Dive, February 9, 2017
“Evaluate Pharma predicts the drug could eventually command sales of over $4.5 billion by 2022 (which would accrue to both Sanofi and Regeneron)…”

15 läkemedel som kan nå blockbusterstatus år 2022 Bio Stock, February 8, 2017
“Nu har Evaluate Pharma gjort en prognos över 20 läkemedel med hög försäljningspotential som väntas nå marknad under 2017, och av dessa förutspås 15 av dem nå blockbusterstatus inom år 2022…”

Roche, Celgene y BMS liderarán el mercado oncológico en 2022Diagnostics News, February 6, 2017
“Así lo asegura la consultora Evaluate Pharma, que apunta a un incremento anual medio de este mercado del 12,5 por ciento en los próximos seis años. En 2015, este segmento registró unas ventas globales de 83.200 millones de dólares…”

Evaluate Pharma, la top ten dei farmaci che faranno il botto di vendite (nel 2022)RIF Day, February 6, 2017
“Alla domanda prova a rispondere, come a ogni inizio anno, la società specializzata americana Evaluate Pharma,  che ha stilato la classifica dei 10 farmaci che saranno lanciati nel corso del 2017 e che, a suo giudizio, raggiungeranno i fatturati più elevati al termine del prossimo quinquennio…”

I 10 farmaci più attesi del 2017Pharma Star, February 5, 2017
La società americana Evaluate Pharma ha stilato la classifica dei 10 farmaci che saranno lanciati nel corso del 2017 e che raggiungeranno i fatturati più elevati...”

Look back at pharma news to Feb 3The Pharma Letter, February 5, 2017
“Monday’s US district court ruling means that a generic version of the 40mg formulation could be on the market as soon as February, several months earlier than expected, says EP Vantage, the editorial arm of the Evaluate group…”

Sanofi Pasteur rolls out Quadracel in the U.S. to take on GSK's Kinrix Zerunbio, February 4, 2017
“In a September 2016 report, EvaluatePharma predicted Pentacel would be the fourth best-selling vaccine in 2022, with Pediarix trailing right behind. The report put their sales numbers that year at $1.75 billion and $1.32 billion respectively…”

Top 10 U.S. patent losses of 2017 FiercePharma, February 4, 2017
“Strattera will lose its patent protection May 26, according to EvaluatePharma and Drug Patent Watch. Lilly itself has guided for May 2017 but

didn’t specify a date…”

Brexit: Dudas, preguntas y respuestas sobre cómo afectará al sector farmacéutico-sanitario im farmacias, February 3, 2017
EP Vantage lanzaba en octubre algunas ideas de lo que podrían ser las implicaciones del Brexit para las industrias biológicas, ahora ampliadas con un nuevo estudio en colaboración con Evaluate Pharma llamado 'Brexit: Laying out a path for UK healthcare'…”

Fondos de inversión relacionados con la investigación del cancer Capital Radio, February 3, 2017
“Según datos de EvaluatePharma, la industria farmacéutica crecerá en un 6,3% por año, llegando a la cifra de 1,12 trillones de dólares en 2022…”

Quels seront les médicaments stars lancés cette année ?La Tribune, February 3, 2017
“Après l'échec des tentatives de rachat d'Actelion et de Medivation, le laboratoire français compte particulièrement sur ce potentiel blockbuster qui pourrait dépasser les 4 milliards de dollars par an en 2022, selon une étude du cabinet Evaluate

Pharma...”

The top 15 would-be blockbusters in the pipeline prepping for a 2017 launch Endpoints, February 3, 2017
“Every year Evaluate Pharma likes to do its breakdown of the top 20 small molecules and biologics aiming to hit the market, ranked by estimated 2022 sales…”

В конце 2016 г. рынок слияний/поглощений в фармотрасли взял паузу перед выборами в США recipe.ru, February 3, 2017
“исключением и фармотрасль. Активность в области M&A фактически заморозилась. Исключением стали лишь две компании – Pfizer и Shire, пишет Evaluate Pharma…”

Компания Pfizer стала абсолютным лидером мирового фармацевтического рынка Pharma Mafia, February 2, 2017
“EvaluatePharma опубликовала прогнозный рейтинг крупнейших фармацевтических компаний в 2017 году…”

Ventas de medicamentos huérfanos se duplicarán en próximos 5 años PMFarma, February 1, 2017
“La IV EvaluatePharma Orphan Drug Report reúne los análisis necesarios para entender cómo funciona y funcionará el mercado de medicamentos huérfanos desde 2017 y hasta 2022…”

НОВАЯ ЭРА: В 2017 ГОДУ РЕЙТИНГ ТОП-10 МИРОВЫХ ФАРМКОМПАНИЙ СУЩЕСТВЕННО ИЗМЕНИТСЯ Pharm.net.ua, February 1, 2017
“EvaluatePharma опубликовала прогнозный рейтинг крупнейших фармацевтических компаний в 2017 году…”

Ein Jahr der Weichenstellung für die Medizintechnikbranche DeviceMed, February 1, 2017
“Obwohl laut einer Erhebung von Evaluate-MedTech noch im Jahr 2015 gerade einmal zehn Unternehmen der Medizintechnikbranche 37 Prozent des weltweiten Umsatzes auf sich vereint haben, schaut die Branche immer stärker auf Start-ups…”

Annual Report - MedAdNews, February issue
“According to recent EvaluatePharma analysis, Dupixent is forecasted to generate sales of $4.56 billion in 2022 based on its anticipated 2017 launch…”


Additional Coverage from Kaiser Health and NPR Series:
Evaluate’s dependable information on drug prices and analysis of the orphan drug market was essential to reporting for the “Orphan Drug Machine” series published on KHN.org and NPR Shots. Audio stories aired on NPR’s Morning Edition and All Things Considered. The audio stories are linked in each of the stories below.
 
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies -
KHN
 
Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies - NPR
 
The second story, which includes the story of a patient in Connecticut, posted online with an audio story to follow.
 
Sky-High Prices For Orphan Drugs Slam American Families And InsurersKHN 


High Prices For Orphan Drugs Strain Families And Insurers - NPR


 

 January 2017

Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies – NPR, January 17, 2016

"Orphan drugs now account for seven of the 10 top-selling drugs of any kind, ranked by annual sales, according to EvaluatePharma."

2016 Saw Slump in FDA Approvals, but 2017 Could be Return to Form - PharmaPhorum, January 2, 2017
“According to Evaluate Pharma, the drug could tip $2.87 billion in revenue by 2021. Additional big hitters this year include Roche's multiple ...”

Healthcare Policies, R&D Investments, and Drug Approvals Will Test Bio/Pharma - Pharmaceutical Technology, January 2, 2017
“The results of the election may have shifted that opinion already, Evaluate Pharma suggests…”

Allergan Wraps up 2016 M&A with LifeCell Buy for $2.9 billion; Analysts Lavish Kudos all Around - Monday Morning, January 4, 2017
“The companies should be a reasonable strategic fit, says EP Vantage, with LifeCell’s tissue matrix grafts fitting with Allergan’s reconstructive breast surgery products, for example…"

Here’s an Infographic of Drug Patents Expiring in 2017 - BioHealth Innovation, January 5, 2017
“EP Vantage, the editorial arm of market intelligence firm Evaluate Pharma, discussed patent expirations in its 2017 pharma preview report….”

BD News and Analysis for Biotech and PharmaPullan’s Pieces, January 6, 2017
“Evaluate Pharma always does a good job on the state of the industry and predictions…”

When it Comes to PCSK9s, Payers Resisted and Sales Flopped - Medical Marketing & Media: Therapeutic Focus, January 10, 2017
“Evaluate-MedTech experts predict annual sales of cardiology-related devices will reach $62.3 billion by 2020, a 48% leap over 2015 sales of $42.1 billion . . .”

Look back at pharma news to Jan 6 The Pharma Letter, January 8, 2017
“In the battle for dominance in new cholesterol-fighting agents, the scenario for Amgen could scarcely be better, commented EP Vantage, the editorial arm of the Evaluate group…”

Top 25 Cardiovascular Brands, 2015-2016Medical Marketing & Media, January 10, 2017
“Source: sales: EvaluatePharma: journal, Kantar Media…”

CAR-T’s Forge Ahead, Despite Juno Death Nature Biotechnology, 10 January 2017
“Source: EP Vantage/EvaluatePharma (London)…”

Curevac reports another failed cancer vaccineEuropean Biotechnology, January 12, 2017
“According to pipeline analyses from EP Vantage, more than half of the agents paired with PD-1 and PD-L1 inhibitors are small molecules,

chemotherapies and established drugs…”

Farmaci, report di EP Vantage: nel 2016 in campo 12 blockbuster About Pharma, January 12, 2017
“Il lancio di ben 12 prodotti “blockbuster”, l’aumento della produttività, un impatto modesto delle scadenze brevettuali. Sono questi, in estrema sintesi, gli elementi principali che caratterizzeranno il mercato farmaceutico nel 2016 secondo il report “Pharma & Biotech 2016 Preview” pubblicato da EP Vantage…”

Cancer R&D and Drugs Dominate Pharma Deals in 2017 - Wall St Analyst, January 12, 2017
“Cancer is one of the pharmaceutical industry’s biggest markets, with worldwide sales amounting to roughly $80 billion a year and growing more than 10% annually, according to EvaluatePharma and as reported by The Wall Street Journal . . .”

Which Biosimilars Will Upend the Global Market in 2017?CHPI.cn, January 13, 2017
“Global Top 10 Drugs by 2017 Sales (source: EvaluatePharma)…”

Look back at pharma news to Jan 13 The Pharma Letter, January 15, 2017
“Takeda’s $5.2 billion takeout of Ariad Pharmaceuticals dents the hypothesis that biotechs with declining valuations will be the chief M&A targets of 2017, says EP Vantage, the editorial arm of the Evaluate group…”

Farmaci, report di EP Vantage: nel 2016 in campo 12 blockbuster About Pharma, January 16, 2017
“Sono questi, in estrema sintesi, gli elementi principali che caratterizzeranno il mercato farmaceutico nel 2016 secondo il report “Pharma & Biotech 2016 Preview” pubblicato da EP Vantage…”

Mercks F&U-chef udpeger pipeline-juvelMedWatch.dk, January 17, 2017
“Det fortæller Luciano Rossetti, der er direktør med ansvar for forskning og udvikling i koncernens biofarma-afdeling, i et interview med EP Vantage…”

Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies - NPR, Morning Edition, January 17, 2017
“EvaluatePharma notes in its recent report that Humira, as well as a handful of other top drugs, receive less ...”

Look Back to Pharma News to Jan 20 - The Pharma Letter, January 22, 2017
“. . . Also commenting, EP Vantage, the editorial arm of the Evaluate group, said: Step forward Europe’s best capitalized biotech, Forward Pharma . . .”

Top 25 Metabolic Brands, by Sales, 2015-2016 - Medical Marketing & Media, January 23, 2017
“Source: sales, EvaluatePharma: journal, Kantar Media…”

When it Comes to Diabetes, Will Marketers Break with Tradition? - Medical Marketing & Media: Therapeutic Focus, January 23, 2017
“The industry needs breakthrough creative and a focus on brand building that goes beyond ‘ask your doctor if this drug is right for you’ . . . See also: Top 25 metabolic brands, by sales, 2015-2016 . . .”

Look back at news to Jan 27The Pharma Letter, January 29, 2017
“After taking repeated thrashings from Merck & Co in first-line lung cancer Bristol-Myers Squibb was due some good luck, commented EP Vantage, the editorial arm of the Evaluate group…”

Novo Nordisk strikes R&D partnership with Oxford Uni Pharmaphorum, January 30, 2017
“According to EP Vantage, sales could be as high as $2.2 billion by 2022…”

Autoimmune Disease Vies With Cancer to Dominate The Class Of 2017 - Seeking Alpha, January 31, 2017
“Among non-biologicals, meanwhile, the drug to watch is Novo Nordisk’s (NYSE:NVO) once-weekly semaglutide, EvaluatePharma figures suggest (see tables below)….”

The Top 10 Drug Launches of 2017 - FiercePharma, January 31, 2017
“After an unusually slow year for new drug approvals—the FDA greenlighted just 22 meds in 2016—it remains to be seen whether drugmakers can do much better in 2017 . . . according to EP Vantage’s 2017 preview, which ranks the year’s rollouts by 2022 sales . . .”

Top 5 Biologicals from European Biopharma to Launch in 2017 LaBiotech, January 31, 2017
“Still, quantitative predictions can be made for the new year. EP Vantage has put together a report summarizing what to expect from the pharma and biotech industry this year…”

A Look Ahead to the Top 10 Drug Launches of 2017 - MedCityNews, January 31, 2017
“Despite capturing the media’s eye, oncology drugs – including CAR-Ts – will comprise just three out of the top 10 drug launches in 2017, according to life science commercial intelligence firm Evaluate Pharma. It’s proof that headlines don’t always equate to sales. Evaluate is expecting the biggest launch of the year the field of dermatitis, with a drug for primary progressive multiple sclerosis coming in a close second . ..”

Archive

 Evaluate Buzz 2016

 Evaluate Buzz 2015

 Evaluate Buzz 2014

 Evaluate Buzz 2013

 Evaluate Buzz 2012

 Evaluate Buzz 2011